

Joaquín V. Arribas López(DOB December 12th, 1964) ORCID: 0000-0002-0504-0664**Education**

- 1987 Grade in Biochemistry, Autonomous University of Madrid.
 1992 Ph D in Cellular and Molecular Biology, Autonomous University of Madrid.
 2015 Program on Executive Management of Health Institutions, IESE Business School.

Present Positions

- 1997 Group Leader, [Vall d'Hebron Institute of Oncology](#) (VHIO).
 2007 [ICREA Research Professor](#).
 2020 Research Director [Hospital del Mar Barcelona](#).
 Director and Group Leader, [Hospital del Mar Research Institute Barcelona](#) (HMRIB, former IMIM).
 2022 Associate Professor, Department of Medicine and Life Sciences, Universitat Pompeu Fabra.

**Research and Professional Experience**

- 1987-1991 Graduate student, Universidad Autónoma de Madrid. PhD Director: José G. Castaño. Project: Proteasome and autoimmunity.
 Jun-Oct 1990 Frederick Cancer Research Facility, Frederick, Maryland, U.S.A. Director: Luis Parada. Project: Cloning and sequencing of murine trk proto-oncogen.
 1993-1997 Postdoctoral Researcher, Memorial Sloan-Kettering Cancer center & Howard Hughes Medical Institute, New York. Director: Joan Massagué. Project: Activation of transmembrane growth factors.
 1997-2007 Research Faculty, Vall d'Hebron University Hospital, Catalan Institute of Health.
 2003-2010 Head, Medical Oncology Research Program, Vall d'Hebron University Hospital, Catalan Institute of Health.
 2010-2020 Director, Preclinical Research Program, VHIO.
 2017-2020 Scientific Director, [CIBERONC](#).
 2007-2022 Associate Professor, Department of Biochemistry and Molecular Biology, Universidad Autónoma de Barcelona.

Table of Contents

Personal Statement	1
Summary	4
Funding	5
Invited Conferences, oral presentations and organizing committees	12
Patents	16
Thesis supervision	19
Current positions of former postdoctoral laboratory members	20
Miscellanea	21
Publications	23

Personal Statement

After my PhD at Universidad Autónoma de Madrid and a postdoctoral stint at Memorial Sloan Kettering Cancer Center with Dr. Joan Massagué, in 1997 I was recruited by the late Dr. Josep Baselga to start my own group at the Medical Oncology Department, Vall d'Hebron University

Hospital. As an independent researcher, I was committed not only to initiating my own **research lines** but also to building and **managing** a robust translational research program in oncology. This task was particularly challenging given the lack of a tradition of translational research in oncology at Vall d'Hebron University Hospital at the time.

Research Lines

Regarding the research lines developed by my group, I transitioned from an initial focus on the biosynthesis of transmembrane growth factors (see Fernández-Larrea, J. et al. *Mol Cell* 1999; Borrell-Pagés, M. et al. *EMBO J* 2003), initiated during my postdoctoral work, to a focus on receptor tyrosine kinases, particularly HER2 (Anido, J. et al. *EMBO J* 2006). We identified a truncated HER2 fragment, p95HER2, and developed antibodies against it (Parra-Palau et al. *Cancer Res* 2010; Parra-Palau, J. et al. *J Natl Cancer Inst* 2014). These anti-p95HER2 has been instrumental in redirecting lymphocytes through bispecific antibodies (Rius Ruiz, I. et al. *Sci Transl Med* 2018) and via CAR T cells (Arenas, E. et al. *Nat Commun* 2022; Román, M. et al. *Nat Commun* 2024). Notably, the p95HER2 CAR Ts will be tested in a Phase I clinical trial starting in March 2026.

In parallel, we demonstrated that p95HER2 is a potent inducer of senescence (Angelini et al. *Cancer Res* 2013; Zacarias-Fluck M. et al. *J Natl Cancer Inst* 2015). Our characterization of the role of cellular senescence in tumor progression and treatment culminated in discovering the immunosuppressive properties of senescent cells, which compromise the anti-tumor efficacy of chemotherapy (Chaib S. et al. *Nat Cancer* 2024), and the creation of a genetically modified mouse model to monitor and functionally characterize cellular senescence in vivo (Lalinde et al., *Sci Adv* 2026).

In 2020, I established a new research group at Hospital del Mar Research Institute Barcelona (HMRIB). Over these five years, the group has advanced efforts to redirect lymphocytes against cancer cells using next-generation bipartite CAR Ts and developed novel murine models to test CAR Ts in immunocompetent mice. This new group has contributed significantly to our recent findings (Arenas, E. et al. *Nat Commun* 2022; Román, M. et al. *Nat Commun* 2024; and Martínez-Sabadell *Cell Reports* 2022) and have secured competitive funding totaling €2,112,970 managed by the HMRIB.

Management

In parallel with my scientific activities, I developed my management skills by recruiting independent researchers as Head of the Medical Oncology Research Program, which in 2008 integrated into VHIO. At VHIO, I was appointed Director of the Preclinical Research Program, a role I held until 2010, when I became Scientific Director of CIBER-ONC. CIBER is a collaborative research infrastructure with a unique approach—it manages the funds its groups secure, independently of their home institutions. When I took on the role in 2017, CIBER Oncology did not yet exist, so we established it from scratch. Thus, both at Vall d'Hebron and CIBER-ONC, I was responsible for creating research infrastructures from the ground up.

After three years leading CIBER-ONC and with the new infrastructure running smoothly, in 2020, I was offered the Directorship of IMIM (originally Instituto Municipal de Investigaciones Médicas, later rebranded as Instituto Hospital del Mar de Investigaciones Médicas). Since they allowed me to retain my affiliation at VHIO, securing my research continuity, I took on this new managerial challenge. Additionally, I was committed to establishing a new, productive research group at IMIM (see above).

Some highlights of IMIM's achievements under my directorship include:

- Renaming the institute Hospital del Mar Research Institute Barcelona, to better reflect our alignment with Hospital del Mar Barcelona.
- Nearly doubling our total budget, from €24.9M in 2019 to €46.5M in 2025. This increase was partly due to a rise in international funding, including three ERC grants (Starting, Consolidated, and Synergy).
- Recruiting three ICREA research professors and establishing three tenured positions supported by the institute.

- Enhancing our CERCA qualification from B to B+ and to A, securing ISCIII reaccreditation, and achieving Center of Excellence status from the Asociación Española Contra el Cáncer (AECC).

Summary

Funding

Competitive funding:

- Since 1997- €17,826,999
- Since 2020- €5,804,233

The funds for human resources (predoctoral and postdoctoral fellowships are not included) and, in addition, since 2020 we have signed agreements for targeted research with pharmaceutical companies for € 1,700,000.

Invited Conferences, oral presentations and organizing committees

Since 1997 more than 100 participations, many as invited speaker and/or chairman, and including several meeting organizations.

Transference

Five patents, three of them licensed (licensing fees €1,500,000)

Thesis supervision

16 theses defended, all with the maximal mark.

Miscellanea

Currently:

- Coordinator of the Breast and Gynecological Cancers Research Program, CIBERONC
- Member of the External Scientific Committee I+12 and IdiPaz
- Member or reviewing panels: ISCIII (eight years as chair of the technical evaluation committee on cancer), Research Council of Norway, Associazione Italiana per la Ricerca sul Cancro (AIRC). Institut National du Cancer, INCa (two years chairman of the panel) and American Association for Cancer Research (AACR).
- Reviewer of articles for different journals (including Nature Medicine, Nature Cell Biol, Cancer Cell, Nature Cancer, Science Translational Medicine)

Citations

Source, Google Scholar as of January 27th, 2026

- Since 1997 h index: 66; Citations: 18,869
- Since 2021: h-index: 43 Citations: 6,253

Funding

Only competitive grants where Dr. Arribas served as Principal Investigator or Co-Principal Investigator are listed. Since the group's founding in 1997, it has secured competitive funding totaling €17,826,999. Over the last five years (since January 1, 2020), the group has received €5,804,233 in competitive awards. The figure below (Fig. 1) highlights the funding agencies supporting these projects. The funds for human resources (predoctoral and postdoctoral fellowships are not included).

Additionally, the Arribas laboratory receives targeted funding from several pharmaceutical companies to drive translational research projects. Since 2020, these grants total €1,700,000 and involve partnerships with large and mid-sized pharmaceutical companies (including Roche, Novartis, Celgene, Menarini, and Byondis), as well as spin-offs (Mnemo and Rejuversen).




Figure 1. Funding received by the Arribas Laboratory; see details in the text above.

The following list details the individual awards. Projects managed by CIBER, Hospital del Mar Research Institute (where part of the Arribas Laboratory moved in 2020), and Vall d'Hebron Institute of Oncology (where part of the group remains), are listed separately.

CIBER

1. Title: CIBERONC

Funding agency: [Instituto de Salud Carlos III \(ISCIII\)](#)

Institution: CIBER/Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [CB16/12/00449](#)

Duration: 2017 – Present (CIBERONC is a stable cooperative research structure)

Amount: ~€ 85.000 / year (€ 680,000 since 2017)

2. Title: Immune4all

Funding agency: [Instituto de Salud Carlos III \(ISCIII\)](#)

Institution: CIBER/Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [PMP22/00054](#)

Duration: Jan 2023 – Dec 2025 (CIBERONC is a stable cooperative research structure)

Amount: € 300,400

Hospital del Mar Research Institute Barcelona (HMRIB)

3. Title: High-performance CAR Ts against solid tumors

Funding agency: [Instituto de Salud Carlos III \(ISCIII\)](#)

Institution: Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [PI22/00001](#)

Amount: [€ 244,420](#)

Duration: Jan 2023 - Dec 2025

4. Title: Immunotherapy against HER2-positive tumors

Funding agency: [Instituto de Salud Carlos III \(ISCIII\)](#)

Institution: Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [PI19/01181](#)

Amount: [€ 378,000](#)

Duration: January 2020 -December 2022

5. Title: Preclinical development and evolution of second-generation antibodies for the treatment of metastatic colorectal cancer

Funding agency: [Ministerio de Ciencia, Innovación y Universidades](#)

Institution: Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [PMPTA22/00108](#)

Amount: [€ 227,064](#)

Duration: Jan 2023 – Dec 2024

6. Title: Next-generation “off-the-shelf” CAR-NK cells derived from iPSCs for allogeneic immunotherapy of solid tumors. OSCAR-iNK

Funding agency: [Ministerio de Ciencia, Innovación y Universidades](#)

Institution: Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [CPP2021-008350](#)

Duration: Jul 2022 – Jun 2025

Amount: [€ 206,863](#)

7. Title: Immune Redirection

Funding agency: [AGAUR](#) (Agència de Gestió d'Ajuts Universitaris i de Recerca), Departament de Recerca i Universitats

Institution: Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [2021 SGR 00167](#)

Amount: [€ 40,000](#)

Duration: Jan 2022 – Dec 2026

8. Title: Análisis prospectivo de biopsias obtenidas en un ensayo clínico de fase 1 de aumento de dosis, usando células CAR T - HER2 Bispecific en pacientes con tumores sólidos avanzados positivos para p95HER2

Funding agency: [Fundación Mutua Madrileña](#)

Institution: Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [AP183522023](#)

Amount: [€ 90,000](#)

Duration: Jan 2025 – Dec 2027

9. Title: Immune senolysis against breast cancer

Funding agency: [“la Caixa” Foundation](#)

Institution: Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [HR22 00776](#)

Duration: Sept 2023 – Sept 2025

Amount: [€ 500,000](#)

10. Title: Adjusting the affinity of HER2 bispecific T-cell engagers (BiTEs) to improve the safety of armored p95HER2.CAR T cells.

Funding agency: [Asociación Española Contra el Cáncer \(AECC\)](#)

Institution: Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [INNOV235333ARRI](#)

Duration: Jan 2024 – Dec 2025

Amount: € 180,000

11. Title: Redirection of T lymphocytes against senescent cells to treat breast cancer

Funding agency: [World Cancer Research](#)

Institution: Hospital del Mar Research Institute Barcelona (HMRIB)

Reference: [11049](#)

Duration: Jun 2023 – May 2026

Amount: £ 246,624 (€ 296,307)

[Vall d'Hebron Institute of Oncology \(VHIO\)](#)

12. Title: [SGR 2017-2019](#)

Funding agency: Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR/Fons Europeus de Desenvolupament Regional (FEDER) 2014-2020

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: [2017 SGR 532](#)

Amount: € 42,000

Duration: Jan 2018 – Dec 2021

13. Title: [Generation of CAR T cells against FGFR2 S252W in Endometrial Cancer](#)

Funding agency: Fundació La Caixa

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: -

Amount: € 30,000

Duration: 1 Jan 2025 – 31 Dec 2025

14. Title: Redirection of T cells against HER2-driven tumors

Funding agency: [Asociación Española Contra el Cáncer \(AECC\)](#)

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: GCAEC19017ARRI

Duration: Nov 2019 - Nov 2024

Amount: € 1,000,000 (€ 500,000 correspond to the group led by Arribas)

15. Title: Immune Senolysis Against Breast Cancer

Funding agency: [Breast Cancer Research Foundation \(BCRF\)](#)

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: [BCRF-24-008](#)

Duration: October 2024 – October 2026. BCRF has funded the group on a yearly basis since 2007 with approximately \$250,000 per year.

Amount: \$ 250,000 ([4,750,000 \\$ since 2007](#))

16. Title: Overcoming Drug Resistance in HER2-Positive Breast Cancer,

Funding agency: [National Institutes of Health](#)

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: [R01CA244601-01](#)

Duration: Jan 2020 – Jan 2025

Amount: \$ 57,688 (\$ 2,451,574 total)

17. Title: EDIRex: EurOPDX Distributed Infrastructure for Research on patient-derived cancer Xenografts

Funding agency: [European Union](#). Horizon 2020 call H2020-INFRAIA-2016-2017 "Integrating activities for starting communities"

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: [EDIRex](#)

Amount: € 143,868 (Consortium: 5.156.198 €)

Duration: Oct 2017-Oct 2022

18. Title: [COLOSSUS](#)

Funding agency: [European Union](#) (Horizon 2020)

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: SC1-PM-02-2017

Amount: € 442,306 (€ 5,996,359 total)

Duration: Jan 2018-Dec 2023

19. Title: Clinical impact of intratumor heterogeneity in metastatic breast cancer – Cancer Core Europe

Funding agency: European Union (TRANSCAN)

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: AC15/00062

Amount: € 99,825

Duration: Jan 2016-Dec 2018

20. Title: Immunotherapy Against HER2-positive Breast and Gastric Cancers

Funding agency: Instituto de Salud Carlos III (ISCIII)

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: PI16/00253

Amount: € 290,620

Duration: Jan 2017-Dec 2019

21. Title: Immunotherapy against p95HER2 positive breast cancer

Funding agency: Agència de Gestió d'Ajuts Universitaris i de Recerca AGAUR/Fons Europeus de Desenvolupament Regional (FEDER) 2014-2020

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: 2016 PROD 00108

Amount: € 100,000

Duration: Jul 2017 – Jan 2019

22. Title: Therapies against p95HER2-positive breast cancers and cellular senescence induced by p95HER2

Funding body Instituto de Salud Carlos III (ISCIII)

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: PI1202536

Amount: € 510,620

Duration: Jan 2013-Dec 2016

23. Title: Thematic Network of Cooperative Research in Cancer

Funding agency: Instituto de Salud Carlos III (ISCIII)

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: RD12/0036/0042

Amount: € 90,200

Duration: Jan 2016 – Dec 2016

24. Title: Thematic Network of Cooperative Research in Cancer

Funding agency: Instituto de Salud Carlos III (ISCIII)

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: RD12/0036/0042

Amount: € 92,575

Duration: Jan 2013-Dec 2013

25. Title: Premature cellular aging and breast cancer

Funding agency: Sandra Ibarra Foundation

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: —

Amount: € 25,000

Duration: Mar 2013 – Mar 2014

26. Title: Novel strategies to treat HER2-positive breast cancers

Funding agency: Spanish Association Against Cancer

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: —

Amount: \$1,200,000

Duration: Sep 2012-Sep 2017

27. Title: Treatment of the hyperactivation of HER2 in breast cancers

Funding agency: AVON Cosmetics Foundation

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: —

Amount: € 285,333

Duration: May 2012 - May 2015

28. Title: Technologic development of diagnostic and/or therapeutic monoclonal antibodies against the HER2 receptor and its truncated variants

Funding agency: Genome Spain Foundation

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: —

Amount: € 276,300

Duration: May 2009- Dec 2011

29. Title: Grants for consolidated research groups

Funding agency: Agència de Gestió d'Ajuts Universitaris i de Recerca

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: 2009SGR328

Amount: € 44,720

Duration: Jan 2009- Dec 2013

30. Title: Carboxy-terminal fragments of HER2 in the progression and treatment of breast cancer

Funding agency: Instituto de Salud Carlos III

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: PI081154

Amount: € 794,970

Duration: Jan 2009- Dec 2012

31. Title: Thematic Network of Cooperative Research in Cancer

Funding agency: Instituto de Salud Carlos III

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: RD06/0020/0022

Amount: € 1,666,587

Duration: Jan 2007-Dec 2012

32. Title: Identification and characterization of mechanisms and factors involved in the intracellular trafficking of ADAM17

Funding agency: Fundación Mutua Madrileña

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: —

Amount: € 43,200

Duration: May 2007- May 2010

33. Title: Grants for consolidated research groups

Funding agency: Agència de Gestió d'Ajuts Universitaris i de Recerca

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: 2005SGR00612

Amount: \$ 36,600

Duration: Jan 2006- Dec 2008

34. Title: Generation and characterization of transgenic mice expressing carboxy-terminal fragment of the HER2 oncogene in mammary glands

Funding agency: Spanish Ministry of Education and Science

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: SAF2005-03939

Amount: € 232,050

Duration: Jan 2006- Dec 2008

35. Title: Identification and characterization of the mechanism of tumorigenesis mediated by HER2 carboxy terminal fragments

Funding agency: Fundació la Marató TV3

Institution: Vall d'Hebron Institut of Oncology (VHIO)

Reference: 05010

Amount: € 248,750

Duration: Jan 2006- Dec 2008

36. Title: Thematic Network of Cooperative Research in Cancer

Funding agency: Instituto de Salud Carlos III

Institution: Vall d'Hebron Institut of Oncology (VHIO)

Reference: PI051658

Amount: € 196,350

Duration: Jan 2006- Dec 2006

37. Title: Functional and structural characterization of a novel product of the proto-oncogene HER2. Therapeutic implications in breast cancer

Funding agency: Spanish Association Against Cancer

Institution: Vall d'Hebron Institut of Oncology (VHIO)

Reference: —

Amount: € 300.000

Duration: February 2005- February 2008

38. Title: Identification of the degradome of the metalloprotease disintegrin TACE: relevance in breast cancer progression

Funding agency: "La Caixa" Foundation

Institution: Vall d'Hebron Institut of Oncology (VHIO)

Reference: BM05-208-00

Amount: 137.000 euros

Duration: May 2005 – May 2008

39. Title: Signaling and Membrane Trafficking in Transformation and Differentiation

Funding agency: European Union (STREP)

Institution: Vall d'Hebron Institut of Oncology (VHIO)

Reference: FP6-503228

Amount: € 234,000

Duration: Jan 2004- Dec 2006.

40. Title: Cancer Genomics. Tumor genotyping

Funding agency: Instituto de Salud Carlos III

Institution: Vall d'Hebron Institut of Oncology (VHIO)

Reference: C03/10

Amount: € 1,002,319 euros

Duration: Jan 2003- Dec 2005

41. Title: Grants for consolidated research groups

Funding agency: Agència de Gestió d'Ajuts Universitaris i de Recerca

Institution: Vall d'Hebron Institut of Oncology (VHIO)

Reference: 2002SGR00019

Amount: € 48,000

Duration: Jan 2003- Dec 2005

42. Title: EMBO Special Grant

Funding agency: Spanish Ministry of Education and Science

Institution: Vall d'Hebron Institut of Oncology (VHIO)

Reference: 2001-5069-E

Amount: € 44,500

Duration: Jan 2003- Dec 2003

43. Title: Role of the shedding of HER2-receptor ligands in tumor progression. Papel del shedding de los ligandos de receptores HER en el desarrollo y progresión tumoral

Funding agency: Instituto de Salud Carlos III

Institution: Vall d'Hebron Institut of Oncology (VHIO)

Reference: PI021003

Amount: € 51,175

Duration: Jan 2003-Dec 2005

44. Title: Characterization and identification of the components of the machinery of the transport of NMDA receptor to the cell surface

Funding agency: Fundació la Marató TV3

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: 01810

Amount: € 101,198

Duration: Jan 2002- Dec 2004

45. Title: Shedding of pro-Transforming Growth Factor-alpha role of metalloprotease-disintegrins and pro-protein convertases

Funding agency: EMBO Young Investigator Programme

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: 450

Amount: € 90,000

Duration: Jan 2002- Dec 2004

46. Title: Identification and characterization of the mechanism of transport of proTGF-alpha to the cell surface

Funding agency: Spanish Ministry of Education and Science

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: SAF2000-0203

Amount: 162.624 euros (27.104.000 pesetas)

Duration: Jan 2001-Dec 2003

47. Title: Regulation of the Adamalysins and the ubiquitin-proteasome in the proteolytic processing of the betaAPP

Funding agency: "La Caixa" Foundation

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: 99/0020-1

Amount: € 51,750 euros (8.625.000 pesetas)

Duration: Jan 1998- Dec 2000

48. Title: Role of adamalysins in the generation of the Abeta peptide

Funding agency: Fundació la Marató TV3

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: 036/97

Amount: € 94,239

Duration: Jan 1998- Dec 2000

49. Title: Identification and characterization of the factors involved in the activated cleavage of transmembrane growth factors

Funding agency: Spanish Ministry of Education and Science

Institution: Vall d'Hebron Institute of Oncology (VHIO)

Reference: SAF97-0229

Amount: € 113,022 (18.837.000 pesetas)

Duration: Jan 1997- Dec 1999

Invited Conferences, oral presentations and organizing committees

(selected among more than 100 participations)

1. Meeting: 50 FEBS Congress
Venue: Maastrich, The Netherlands
Date: July 4-6, 2026
Participation: Invited speaker
Title: Novel Targets for Immune Redirection
2. Meeting: EACR - Next Generation Immunotherapies
Venue: Virtual Event
Date: February 24-25, 2026
Participation: Invited speaker
Title: Immune redirection against solid tumors-
3. Meeting: 2st VHIO-BBVA Foundation Symposium on Cell-Based Therapies in Oncology
Venue: Barcelona, Spain
Date: November 13th-14th, 2025
Participation: Organizer, Session Chair and Invited Speaker
Title: Novel Targets for Immune Redirection
4. Meeting. Spanish Association Against Cancer (AECC)
Venue: Ibiza, Spain
Date: June 13th, 2025
Participation: Invited Conference
Title: Closer to a new immunotherapy for breast cancer
5. Meeting: III International Immunology Day Symposium
Venue: Barcelona, Spain
Date: April 29th, 2025
Participation: Invited Conference
Title: CAR-T Therapy in Solid Tumors
6. Meeting: Awarding of the CSIC “Santiago Ramón y Cajal” Clinical Research Merit Diploma
Venue: Madrid, Spain
Date: March 25th, 2025
Participation: Keynote Conference
Title: Redirecting the immune system against cancer
7. Meeting: Second Meeting of Researchers Against Cancer, Spanish Association Against Cancer (AECC)
Venue: Madrid, Spain
Date: March 4th, 2025
Participation: Keynote Conference
Title: Transforming Ideas into Therapies: The Story of a Passionate Journey
8. Meeting: 1st VHIO-BBVA Foundation Symposium on Cell-Based Therapies in Oncology
Venue: Barcelona, Spain
Date: November 29th-30th, 2023
Participation: Session Chair and Invited Speaker
Title: Immune redirection against HER2-driven tumor
9. Meeting: Keystone Symposia on Multispecific Immune Cell Engagers for Cancer Immunotherapy and Next Generation Antibody Therapeutics: From Discovery to Patient
Venue: Fairmont Banff Springs, Banff, AB, Canada
Date: February 19th-21th, 2023
Participation: Session Chair and Invited Speaker
Title: IFN-Signaling and Acquired Cancer Cell Resistance to T Cell Engagers
10. Meeting: 2022 Mammary Gland Biology GRC
Venue: Il Ciocco, Italy
Date: June 7th-12th, 2022

Participation: Invited Conference

Title: Safe redirection of cytotoxic lymphocytes against breast cancer cells

11. Meeting: 6th CAR-TCR Summit

Venue: Remote

Date: August 30th-September 2nd, 2021

Participation: Invited conference

Title: CAR-T Therapies to turn back time on senescence-associated pathologies

12. Meeting: Humanized Mice Journal Club

Venue: Remote

Date: June 8th, 2021

Participation: Invited conference

Title: Humanization of mice to model anti-tumor therapies

13. Meeting: 17th ASEICA International Congress

Venue: Remote

Date: November 4th-6^h, 2020

Participation: Discussion Panel

Title: Cooperative Groups

14. Meeting: 2020 Oncology Congress for Students

Venue: Pamplona, Spain

Date: February 27th-29th, 2020

Participation: Plenary Lecture

Title: Translational Cancer Research

15. Meeting: Mobilizing specific T cells against cancer

Venue: INSERM, Paris

Date: Jul 5th, 2019

Participation: Invited Conference

Title: Redirection of T-cells against HER2-positive cancers

16. Meeting: Cancer and the immune system

Venue: Bellairs Research Institute, Holetown, Barbados

Date: Jan 20th-27th, 2017

Participation: Invited Conference

Title: Immunotherapy against HER2-positive breast cancer

17. Meeting: Towards Predictive Cancer Models, Vall d'Hebron Institute of Oncology

Venue: Vall d'Hebron Institute of Oncology, Barcelona

Date: May 26th-27th, 2016

Participation: Co-Organizer with Laura Soucek

18. Meeting: Cancer Therapeutic Resistance: Progress and Perspectives. B-Debate

Venue: CaixaForum, Barcelona

Date: April 7th-8th, 2016

Participation: Co-Organizer with Miquel Angel Pujana

19. Meeting: Cell Communication in Translational Research

Venue: Weizmann Institute of Science, Israel

Date: January 22nd-23rd, 2015

Participation: Co-Organizer with Irit Sagi

Title: Targeting intercellular communication during breast cancer progression

20. Meeting: Gordon Research Conference on Matrix Metalloproteinases on Regulated Proteolysis of Cell Surface Proteins

Venue: Ventura CA.

Date: March 30th- April 4th, 2014

Participation: Invited conference

Title: Ectodomain Shedding During Oncogene-Induced Senescence

21. Meeting: Gordon Research Conference on Matrix Metalloproteinases

Venue: Lucca, Barga, Italy

Date: May 19th-24th, 2014

Participation: Invited conference

Title: ADAM17 mediates the protumorigenic effect of p95HER2-induced senescent cells

22.Meeting: 46th Sandbjerg meeting on membrane transport

Venue: Sandbjerg Estate, Sønderborg, Denmark,

Date: May 12th-14th, 2014

Participation: Invited conference

Title: Protein ectodomain shedding during oncogene-induced senescence

23.Meeting: Global Breast Cancer Conference

Venue: Seoul, Korea

Date: October 5th - 7th, 2011

Participation: Invited conference

Title: HER2 Pathway Biology. Focusing on p95HER2,.

24.Meeting: International Symposium on Intracellular Proteolysis and Cancer

Venue: Valencia, Spain

Date: October 26th, 2011

Participation: Invited conference

Title: Proteolytic remodeling of the cell surface during breast cancer progression and

25.Meeting: Gordon Research Conference on Regulated Proteolysis of Cell Surface Proteins

Venue: Davidson, NC, USA

Date: July 10th-15th, 2011

Participation: Chairman, session on Factors that influence ADAM-dependent processing

26.Meeting: CNIO Frontiers Meetings. Breast Cancer

Venue: CNIO, Madrid, Spain

Date: February 7th-9th, 2011

Participation: Organizer

Title: Hyperactivation of HER2 and anti-HER2 therapies

27.Meeting: 5th General Meeting of the International Proteolysis Society

Venue: Patras, Greece

Date: October, 21st-23rd 2007

Participation: Invited conference

Title: Proteomic identification and characterization of ADAM substrates

28.Meeting: Gordon Research Conference on Matrix Metalloprotease

Venue: Il Ciocco, Italy

Date: June 6th-7th, 2007

Participation: Invited conference

Title: Identification and characterization of novel ADAM and ADAMTS substrates

29.Meeting: Metzincin Metalloproteases in Health and Diseases

Venue: Ascona, Switzerland,

Date: September 24th-27th, 2006

Participation: Invited conference

Title: Proteomic identification and characterization of ADAM substrates

30.Meeting: 3rd Annual Symposium on Anti-Signaling Strategies in Human Neoplasia

Venue: Barcelona, Spain

Date: September 16th, 2004

Participation: Invited conference and chairman

Title: Characterization of a novel product of the oncogene ErbB2

31.Meeting: Gordon Research Conference on Matrix Metalloproteases

Venue: Big Sky, MT, USA

Date: August 18th-21st, 2003

Participation: Invited conference

Title: Role of TACE in EGFR-Ligand Activation and Tumor Development

32.Meeting: Inaugural Conference, XII National Congress on Bioenergetics and Biomembranes

Venue: Querétaro, Mexico

Date: November 17th-20th, 2001

Participation: Invited inaugural conference

Title: Biosynthesis and shedding of proTGF- α , a prototypical ligand of the Epidermal Growth Factor Receptor

33.Meeting: 26th European Peptide Symposium

Venue: Montpellier, France

Date: September 10th-14th, 2000.

Participation: Plenary Lecture,

Title: Role of protein ectodomain shedding in biological functions

34.Meeting: 11th UK Adhesion Meeting

Venue: London, UK

Date: September 5th 2000

Participation: Invited conference and chairman

Title: Protein ectodomain shedding in the absence of TACE

35.Meeting: Gordon Research Conference on Matrix Metalloproteases

Venue: New London, New Hampshire, USA

Date: August 8th-10th, 1999

Participation: Invited conference

Title: PDZ proteins and intracellular trafficking

36.Meeting: Biochemical Society Meeting, Symposium on Membrane Protein Secretases

Venue: Leicester, UK

Date: September 26th-28th, 1998

Participation: Invited conference

Title: Mechanisms controlling the shedding of transmembrane molecules.

Patents

Of the five main patents filed by the Arribas laboratory, three have been licensed to GlaxoSmithKline, Innovent, and Mnemo, generating licensing fees totaling €1,500,000 (see Fig. 2). In addition to these patents, we are in the process of filing two new applications: the protection of viable HER2 knock-in mice and antibodies specific to a mutant receptor tyrosine kinase that drives the progression of certain tumors.




Figure 2. Licenses of the patents generated by the Arribas laboratory

The following list details some aspects of the patents; extensive information is available on the [WIPO](https://www.wipo.int/patdb/search/quick) website.

- Title:** Immune cells expressing chimeric antigen receptors and bispecific antibodies and uses thereof

Inventors: Joaquin Arribas; Macarena Roman; Ariadna Grinyó i Escuer; Santiago Duro Sánchez; Irene Rius; Vanesa Nogales Trallero

Priority: [PCT/EP2023/057957](#)

Date of filing: 28/03/2023

Application number:

Priority country:

Designated contracting states:

Date of publication of application:

Publication number:

Date of publication and mention of the grant of the patent:

Year granted:

Patent holding body: Vall d'Hebron Institut d'Oncologia (VHIO), Institució Catalana de Recerca i Estudis Avançats (ICREA), Hospital del Mar Research Institute.

Extended:

Companies exploiting it:
- Title:** CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR P95HER2 AND USES THEREOF

Inventors: Joaquin Arribas; Irene Rius; Macarena Roman; Alena Gros; Carlos Alberto Fajardo; Christian Klein; Ekkehard Moessner.

Priority: [EP20382457.8](#)

Date of filing: 28/05/2020

Application number: 20382457.8

Priority country: European Patent Application

Designated contracting states: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Date of publication of application:

Publication number:

Date of publication and mention of the grant of the patent:

Year granted:

Patent holding body: Vall d'Hebron Institut d'Oncologia (VHIO), Institució Catalana de Recerca i Estudis Avançats (ICREA)

Extended:

Companies exploiting it: Pending to execute an agreement with Mnemo Therapeutics

3. Title: Bispecific T cell activating antigen binding molecules

Inventors: Marina Bacac, Anne Freimoser-Grundschober, Sylvia Herter, Christian Klein, Joaquín Arribas, Rocío Vicario

Priority date: Sept, 30th, 2016

Application number: EP 16191933.7

Priority country: European Patent Application

Date of publication:

Designated contracting states: -

Designated extension states: -

Year granted: -

Patent holding body: F. Hoffmann-La Roche AG

Countries extended: Europe

Companies exploiting it: F. Hoffmann-La Roche AG

4. Title: ANTIBODIES AGAINST HER2 TRUNCATED VARIANT CTF-611

Inventors: Joaquin Arribas; Kim Pedersen; Davide Angellini; Josep Lluís Parra; Josep Baselga

Priority: 07/12/2009 EP 0930183.5

Date of filing: 07/10/2010

Application number: 10193969.2

Priority country: European Patent Application

Designated contracting states: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Date of publication of application: 24/08/2011 Bulletin 2011/34

Publication number: EP2360187B1

Date of publication and mention of the grant of the patent: 20/04/2016 Bulletin 2016/16

Year granted: 2016

Patent holding body: Vall d'Hebron Institut d'Oncologia (VHIO), Institució Catalana de Recerca i Estudis Avançats (ICREA)

Extended: Europe, United States, Japan

US patent application

Date of filing: 06/12/2010

Application number: 12/961,004

Publication Date: 09/06/2011

Publication Number: US 2011/0135653A1

Companies exploiting it: GSK until 2019. Pending to be licensed to Innovent. Only active in USA.

5. Title: Method for diagnosing cancers expressing the HER2 receptor or its truncated variants

Inventors: Arribas J, Parra-Palau JL, Pedersen, K, Laos S, Angellini PD, Baselga, J

Priority: 08/06/2008 P200801652

International filing date: 05/06/2009

Application number: 09772265.6

International application number (patent cooperation treaty - pct): PCT/EP2009/056976

US application number: 12479035

Priority country: Spain

Designated states: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NL NO NZ OM PG PH PL PT RO RS RU SC SD SE SG SK SL SM ST SV SY TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW.

Regions: ARIPO (BW, GH GM, KE, LS MW NA SD SL SZ TZ UG ZM ZW, Eurasian (AM AZ BY KG KZ MD RU TJ TM, European (AT, BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR) OAPI (BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG).

Companies exploiting it: GSK until 2019. Pending to be licensed to Innovent. Only active in USA.

Thesis supervision

1. Title: Novel Strategies to Improve the Efficacy and Safety of Antibody Drug Conjugates for HER2-Positive Breast Cancer
 Author: Santiago Duro Sánchez
 University: Universitat Autònoma de Barcelona
 Rank: Cum Laude.
 Date: 9/5/2025
2. Title: Unravelling the dual role of senescent cells in breast cancer progression
 Author: Marta Lalinde.
 University: Universitat Autònoma de Barcelona
 Rank: Cum Laude.
 Date: 17/10/2024
3. Title: CAR T cells targeting HER2-positive tumors.
 Author: Macarena Román Alonso.
 University: Universitat Autònoma de Barcelona
 Rank: Cum Laude.
 Date: 03/04/2024
4. Title: Uncovering cancer immunotherapy resistance: The key role of tumor intrinsic IFN γ response in T cell-based therapies
 Author: Alex Martínez-Sabadell Aliguer.
 University: Universitat Autònoma de Barcelona
 Rank: Cum Laude.
 Date: 18/12/2023
 Co-director: Enrique Arenas
5. Title: T cell redirection as immunotherapeutic approach against HER2-positive breast cancer
 Author: Irene Rius
 University: Universitat Autònoma de Barcelona
 Faculty: Medicine
 Rank: Cum Laude. Pioneer Award 2020
 Date: 29/11/2019
6. Title: Targeting the Mek1/2-Erk1/2 signaling pathway in pancreatic cancer
 Author: Faiz Bilal Espejo
 University: Autonomous University of Barcelona
 Faculty: Medicine
 Rank: Cum Laude
 Year: 30/09/2019
7. Title: Mechanisms of resistance to TDM-1 in HER2-positive breast cancer
 Author: Junjie Zhang
 University: Autonomous University of Barcelona
 Faculty: Medicine
 Rank: Excellent
 Year: 20/06/2018
 Co-director: Verónica Rodilla
8. Title: Immunotherapy against HER2-positive breast cancer
 Author: Rocío Vicario
 University: Autonomous University of Barcelona
 Faculty: Medicine
 Rank: Cum Laude
 Year: 2017
9. Title: Mechanisms behind the oncogene-induced senescence (OIS) - oncogene-induced apoptosis (OIA) decision in cells expressing p95HER2
 Author: Cristina Bernadó Morales
 University: University of Barcelona

Faculty: Pharmacy

Rank: Cum Laude

Year: 2015

10. Title: Hyper-activation of HER2 through the production of carboxy-terminal fragments

Author: Pier Davide Angelini

University: Autonomous University of Barcelona

Faculty: Biology

Rank: Cum Laude

Year: 2014

11. Title: Role of the intracellular domain of TACE/Adam17 on the regulation of its catalytic activity

Author: Maria Teresa Villanueva de la Torre

University: Autonomous University of Barcelona

Faculty: Biology

Rank: Cum Laude

Year: 2007

12. Title: Characterization of the degradoma of Adam17: role of endocytosis on the role of pro-TGF- α activity and identification of novel metalloprotease substrates

Author: Joan Josep Bech Serra

University: Autonomous University of Barcelona

Faculty: Biology

Rank: Cum Laude

Year: 2006

13. Title: Novel mechanisms of tumorigenesis driven by the proto-oncogen HER2: Therapeutic implications in breast cancer

Author: Judit Anido Folgueira

University: University of Barcelona

Faculty: Biology

Rank: Cum Laude

Year: 2006

14. Title: Intracellular trafficking and activation of the metalloprotease Adam17/TACE

Author: Soraya Ruiz Paz

University: University of Barcelona

Faculty: Biology

Rank: Cum Laude

Year: 2005

15. Title: Shedding of the transforming growth factor- α during tumor generation and progression. PDZ proteins involved in the intracellular transport of proTGF- α

Author: Maria Borrell Pagés

University: University of Barcelona

Faculty: Biology

Rank: Cum Laude

Year: 2002

16. Title: Intracellular trafficking and shedding of the transforming growth factor- α .

Author: Anna Merlos Suárez

University: University of Barcelona

Faculty: Biology

Rank: Cum Laude

Year: 2001

Current positions of former postdoctoral laboratory members

More twenty former postdocs that have finished their work at the Arribas laboratory have followed scientific careers. One is Scientific Director in ONA pharmaceuticals, one Regional Medical Manager, International in Pfizer One is the General Director of the Department of

Innovation and Public Research (Regional Government of Galicia, Spain), three work managing research projects in pharmaceutical companies (J. Uriach & Cia, Novartis, Amgen), two are assistant professors (University of Barcelona and University Rovira I Virgili, Tarragona, Spain,) three are staff Scientists (Center of Molecular Biology “Severo Ochoa”, Madrid; Neuroscience Institute, Alicante, Spain; and the Technologic Center form Nutrition and Health, Reus, Spain) and four are postdoctoral fellows in different labs around the world (VHIO, Barcelona; VIB, Leuven, Albert Einstein Med New York).

Miscellanea

2009 - present	Member of the External Scientific Committee, Instituto de Investigación Hospital Universitario 12 de Octubre, Madrid (I12+i (https://imas12.es))
2009 - present	Member of the External Scientific Committee, Instituto de Investigación Hospital Universitario La Paz, Madrid (IdiPaz (2017 www.idipaz.es))
2022 - present	Member of reviewing panels for the Research Council of Norway.
2021 - present	Member of reviewing panes for AIRC (Fondazione AIRC per la Ricerca sul Cancro)
2025 - present	Member of reviewing panels for AACR (American Association for Cancer Research)
2019 - 2020	Chairman of the PLBIO Evaluation committee. INCa (France).
2002 - 2004.	Reviewer of grants for the “The Wellcome Trust” (United Kingdom), the “Swiss Cancer League” (Switzerland)
2021 - 2025	Coordinator of the Breast and Gynecological Cancers Research Program, CIBERONC.
2017 - 2020	Scientific Director, CIBERONC (https://www.ciberonc.es)
2018 - 2020	Chairman of the External Scientific Committee, Instituto Hospital del Mar de d'Investigaciones Médicas (www.imim.es)
2012 - 2016	Coordinator of the Breast Cancer Programme within the Spanish Network of Cooperative Cancer Research (RTICC) (http://www.rticc.org).
2006 - 2016	Member of the Executive Committee, Cancer Research Network, Instituto de Salud Carlos III (http://www.isciii.es)
2002 - present	Arribas group was designated “Consolidated Group” by the Department of Universities, Research and Information (DURSI), Generalitat de Catalunya (Catalan Government).
2008 - 2011	Scientific representative (Spain) in EATRIS (European Advanced Translational Research Infraestructure in Medicine) (www.eatris.eu)
2005 - 2018	Member of the Editorial Board. The Journal of Biological Chemistry
2004 - 2011	President of the Commission for the evaluation of research project proposals on Cancer. Fondo de Investigación Sanitaria (Health Research Fund), Insituto de Salud Carlos III (“Carlos III” Health Institute)
2003	Beckman Coulter Award to the Best Young Spanish Investigator in Biochemistry and Molecular Biology. Spanish Society of Biochemistry and Molecular Biology (SEBBM).
2002 - 2006	President of the Scientific Council. Vall d'Hebron University Hospital Research Institute.
2002 - 2005	Scientific coordinator of the Node Vall d'Hebron, Network of Cancer Centers supported by the Instituto de Salud Carlos III.
2001	Selected to participate in the YIP program (Young Investigator Program) promoted by the European Molecular Biology Organization (EMBO).

- 1998 - present Member of the Spanish Society of Biochemistry and Molecular Biology (SEBBM).
- 1996 - present Reviewer of papers for the following journals: Nature Medicine, Nature Cell Biol, Cancer Cell, Cell Reports, J Biol Chem, Eur J Biochem, J Cell Sci, EMBO J, J Cell Biol, Gene Dev, Exp. Cell Res, Can Res, Clin Can Res, Nature Cancer, Science Translational Medicine

Publications

2025

1. Marta Lalinde-Gutiérrez, Sandra Pérez-Ramos, Verónica Rodilla, Júlia Perera-Bel, Pau Berenguer-Molins, Lara Nonell, Irene Agustí-Barea, Christopher George and **Joaquín Arribas**. Immunosuppressive macrophages determine the effect of cellular senescence on tumor progression (2026) **Science Advances** 12, 1 DOI: 10.1126/sciadv.adx2988

2024

2. Macarena Román, Ariadna Grinyó-Escuer, Santiago Duro-Sánchez, Irene Rius-Ruiz, Marta Bort-Brusca, Marta Escorihuela, Susana Maqueda-Marcos, Sandra Pérez-Ramos, Judit Gago, Vanesa Nogales, Martín Espinosa-Bravo, Vicente Peg, Santiago Escrivá-de-Romaní, Laia Foradada, Laura Soucek, Irene Braña, Vladimir Galvao, Silvia Martín-Lluesma, Ekkehard Moessner, Christian Klein, Elena Garralda, Cristina Saura & **Joaquín Arribas**. Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors (2024) **Nature Communications**, 15, 9589

Collaborations

3. Selim Chaib, José Alberto López-Domínguez, Marta Lalinde-Gutiérrez, Neus Prats, Ines Marin, Olga Boix, Andrea García-Garijo, Kathleen Meyer, María Isabel Muñoz, Mònica Aguilera, Lidia Mateo, Camille Stephan-Otto Attolini, Susana Llanos, Sandra Pérez-Ramos, Marta Escorihuela, Fatima Al-Shahrour, Timothy P Cash, Tamara Tchkonja, James L Kirkland, María Abad, Alena Gros, **Joaquín Arribas**, Manuel Serrano. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2 (2024) **Nature cancer** 5, 448-462.
4. Andrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, Joanna Domènech-Vivó, Eduardo García-Galea, Alejandro Moles-Fernández, Flaminia Pedretti, Heura Domènech, Olga Rodríguez, Marta Guzmán, Enrique J Arenas, Helena Verdager, Fernando J Calero-Nieto, Sara Talbot, Luis Tobalina, Elisabetta Leo, Alan Lau, Paolo Nuciforo, Rodrigo Dienstmann, Teresa Macarulla, **Joaquín Arribas**, Orland Díez, Sara Gutiérrez-Enríquez, Josep V Forment, Mark J O'Connor, Mark Albertella, Judith Balmaña, Violeta Serra. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models (2024) **Genome Medicine** 16, 107.
5. Gemma Serra-Bardenys, Enrique Blanco, Carmen Escudero-Iriarte, Queralt Serra-Camprubí, Jessica Querol, Laura Pascual-Reguant, Beatriz Morancho, Marta Escorihuela, Natalia Soledad Tissera, Anna Sabé, Luna Martín, Sandra Segura-Bayona, Gaetano Verde, Riccardo Aiese Cigliano, Alba Millanes-Romero, Celia Jerónimo, Joan Pau Cebrià-Costa, Paolo Nuciforo, Sara Simonetti, Cristina Viaplana, Rodrigo Dienstmann, Mafalda Oliveira, Vicente Peg, Travis H Stracker, **Joaquín Arribas**, Francesc Canals, Josep Villanueva, Luciano Di Croce, Antonio García de Herreros, Tian V Tian, Sandra Peiró. LOXL 2-mediated chromatin compaction is required to maintain the oncogenic properties of triple-negative breast cancer cells (2024) **The FEBS Journal** 291, 2423-2448.
6. Dalia de la Fuente-Vivas, Vincenzo Cappitelli, Rocío García-Gómez, Sara Valero-Díaz, Camilla Amato, Javier Rodríguez, Santiago Duro-Sánchez, Alexander von Kriegsheim, Michael Grusch, José Lozano, **Joaquín Arribas**, Berta Casar, Piero Crespo. ERK1/2 mitogen-activated protein kinase dimerization is essential for the regulation of cell motility (2024) **Molecular Oncology** 19, 452-473
7. Mariana Yáñez-Bartolomé, Queralt Serra-Camprubí, Enrique J Arenas, Marta Escorihuela, Florian Castet, Carles Fabregat-Franco, Jessica Querol, Joaquín Arribas, Sandra Peiró, Teresa Macarulla, Tian V Tian. Generation of Metastatic Cholangiocarcinoma Patient-Derived Xenograft Models (2024) **Methods Mol Biol** 2806:139-151

2023

8. Eduardo Pérez Del Río, Macarena Román Alonso, Irene Rius, Fabião Santos, Miquel Castellote-Borrell, Jaume Veciana, Imma Ratera, **Joaquín Arribas***, Judith Guasch*. Three-dimensional cell culture of chimeric antigen receptor T cells originated from peripheral blood mononuclear cells towards cellular therapies (2023) **Cytotherapy** 25, 1293-1299.
9. Ángela Quintana, Enrique Javier Arenas, Cristina Bernado, Jose Fernandez Navarro, Jonatan González, Anna Esteve-Codina, Teresa Moline, Merce Marti, Giuseppe Curigliano, Peter Schmid, Vicente Peg, **Joaquín Arribas***, Javier Cortes. Evaluation of triple negative breast cancer with heterogeneous immune infiltration (2023) **Frontiers in Immunology** 14, 1149747.
10. Santiago Duro-Sánchez, Macarena Román Alonso, **Joaquín Arribas**. Immunotherapies against HER2-positive breast cancer (2023) **Cancers** 4, 1069.

Collaborations

11. Early-stage breast cancer detection in breast milk. Cristina Saura, Carolina Ortiz, Judit Matito, Enrique J Arenas, Anna Suñol, Ágatha Martín, Octavi Córdoba, Alex Martínez-Sabadell, Itziar García-Ruiz, Ignacio Miranda, Clara Morales-Comas, Estela Carrasco, Cristina Viaplana, Vicente Peg, Paolo Nuciforo, Neus Bayó-Puxan, Alberto Gonzalez-Medina, Josep M Miquel, Marina Gómez-Rey, Guillermo Villacampa, Silvia Arévalo, Martín Espinosa-Bravo, Judith Balmaña, Rodrigo Dienstmann, **Joaquin Arribas**, Josep Tabernero, Ana Vivancos, Miriam Sansó. **Cancer discovery** 13, 2180-2191.
12. Laura Pascual-Reguant, Queralt Serra-Camprubí, Debayan Datta, Damiano Cianferoni, Savvas Kourtis, Antoni Gañez-Zapater, Chiara Cannatà, Lorena Espinar, Jessica Querol, Laura García-López, Sara Musa-Afaneh, Maria Guirola, Anestis Gkanogiannis, Andrea Miró Canturri, Marta Guzman, Olga Rodríguez, Andrea Herencia-Roper, **Joaquín Arribas**, Violeta Serra, Luis Serrano, Tian V Tian, Sandra Peiró, Sara Sdelci. Interactions between BRD4S, LOXL2, and MED1 drive cell cycle transcription in triple-negative breast cancer (2023) **EMBO Molecular Medicine** 15, e18459.
13. Queralt Serra-Camprubí, Helena Verdaguer, Winona Oliveros, Núria Lupión-Garcia, Alba Llop-Guevara, Cristina Molina, Maria Vila-Casadesús, Anthony Turpin, Cindy Neuzillet, Joan Frigola, Jessica Querol, Mariana Yáñez-Bartolomé, Florian Castet, Carles Fabregat-Franco, Carmen Escudero-Iriarte, Marta Escorihuela, Enrique J Arenas, Cristina Bernadó-Morales, Noemí Haro, Francis J Giles, Oscar J Pozo, Josep M Miquel, Paolo G Nuciforo, Ana Vivancos, Marta Melé, Violeta Serra, **Joaquín Arribas**, Josep Tabernero, Sandra Peiró, Teresa Macarulla, Tian V Tian. Human metastatic cholangiocarcinoma patient-derived xenografts and tumoroids for preclinical drug evaluation (2023) **Clinical Cancer Research** 29, 432-445.
14. Alessio Fiascarelli, Giuseppe Merlino, Stefania Capano, Simone Talucci, Diego Bisignano, Alessandro Bressan, Daniela Bellarosa, Corrado Carrisi, Alessandro Paoli, Mario Bigioni, Patrizia Tunici, Clelia Irrissuto, Massimiliano Salerno, **Joaquín Arribas**, Elisa de Stanchina, Maurizio Scaltriti, Monica Binaschi. Antitumor activity of the PI3K δ -sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2+ breast cancer. **Breast Cancer Research and Treatment** 1, 13-23.
15. Anna Adam-Artigues, Enrique J Arenas, **Joaquín Arribas**, Aleix Prat, Juan Miguel Cejalvo. AXL-a new player in resistance to HER2 blockade (2023) **Cancer Treatment Reviews**, 102639

2022

16. Martínez-Sabadell, A., Moranco, B., Ruiz, I.R., Escorihuela, M., Luque, A., Chicote, I., Bacac, M., **Arribas, J.***, and Arenas, E.J.*. The target antigen determines the mechanism of acquired resistance to T cell-based therapies (2022) **Cell Reports** 41(3),111430. doi: 10.1016/j.celrep.2022.111430.

17. Martínez-Sabadell A, Ovejero Romero P, **Arribas J**, Arenas EJ. Protocol to generate a patient derived xenograft model of acquired resistance to immunotherapy in humanized mice (2022) **STAR Protoc** 3(4):101712.
18. Santiago Duro-Sánchez, Mercedes Nadal-Serrano, Marta Lalinde-Gutiérrez, Enrique J. Arenas, Cristina Bernadó Morales, Beatriz Moranco, Marta Escorihuela, Sandra Pérez-Ramos, Santiago Escrivá-de-Romaní, Lucía Gandullo-Sánchez, Atanasio Pandiella, Anna Esteve-Codina, Veronica Rodilla, Fred A. Dijcks, Wim H. Dokter, Javier Cortés, Cristina Saura, **Arribas J** (2022) Therapy-induced senescence enhances the efficacy of HER2-targeted antibody–drug conjugates in breast cancer. **Cancer Res** 82, 4670-4679.
19. Martínez-Sabadell, A., Arenas, E. J. and **Arribas J**. IFN- γ signaling in natural and therapy-induced anti-tumor responses (2022) **Clin Cancer Res** 28, 1243-1249

Collaborations

20. Pérez-Núñez I, Rozalén C, Palomeque JÁ, Sangrador I, Dalmau M, Comerma L, Hernández-Prat A, Casadevall D, Menendez S, Liu DD, Shen M, Berenguer J, Ruiz IR, Peña R, Montañés JC, Albà MM, Bonnin S, Ponomarenko J, Gomis RR, Cejalvo JM, Servitja S, Marzese DM, Morey L, Voorwerk L, **Arribas J**, Bermejo B, Kok M, Pusztai L, Kang Y, Albanell J, Celià-Terrassa T. LCOR mediates interferon-independent tumor immunogenicity and responsiveness to immune-checkpoint blockade in triple-negative breast cancer (2022) **Nat Cancer** 3, 355-370.
21. Manuel Gamez-Chiachio; Angela Molina-Crespo; Carmen Ramos-Nebot; Jeannette Martinez-Val; Lidia Martinez; Katja Gassner; Francisco J Ilobet; Mario Soriano; Alberto Hernandez; Marco Cordani; Cristina Bernadó-Morales; Eva Diaz; Alejandro Rojo-Sebastián; Juan Carlos Triviño; Laura Sanchez; Ruth Rodríguez-Barrueco; **Joaquín Arribas**; David Llobet-Navas; David Sarrió; Gema Moreno-Bueno. Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation (2022) **Journal of Experimental & Clinical Cancer Research** 41, 285.
22. Palafox M, Monserrat L, Bellet M, Villacampa G, Gonzalez-Perez A, Oliveira M, Brasó-Maristany F, Ibrahimi N, Kannan S, Mina L, Herrera-Abreu MT, Odena A, Sánchez-Guixé M, Capelán M, Azaro A, Bruna A, Rodríguez O, Guzmán M, Grueso J, Viaplana C, Hernández J, Su F, Lin K, Clarke RB, Caldas C, **Arribas J**, Michiels S, García-Sanz A, Turner NC, Prat A, Nuciforo P, Dienstmann R, Verma CS, Lopez-Bigas N, Scaltriti M, Arnedos M, Saura C, Serra V. High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER + breast cancer. **Nat Commun** doi: 10.1038/s41467-022-32828-6
23. Anderson T Wang , Marta Castroviejo-Bermejo , Urszula M. Polanska , Marta Palafox , Ms. Andrea Herencia-Ropero , Gemma N. Jones , Zhongwu Lai , Joshua Armenia , Filippos Michopoulos , Alba Llop-Guevara , Rachel Brough , Aditi Gulati , Stephen J Pettitt , Krishna C Bulusu , Jenni Nikkilä , Ms. Zena Wilson , Adina M Hughes , Paul W.G. Wijnhoven , Ms. Ambar Ahmed , Alejandra Bruna , Albert Gris-Oliver , Ms. Marta Guzman , Ms. Olga Rodriguez , Ms. Judit Grueso , **Joaquín Arribas** , Javier Cortés , Cristina Saura , Alan Lau , Susan E Critchlow , Brian A Dougherty , Carlos Caldas , Gordon B. Mills , J. Carl Barrett , Josep V Forment , Elaine B. Cadogan , Christopher J Lord , Cristina Cruz , Judith Balmaña , Mark J O'Connor. Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance (2022) **Clin Cancer Res**, **CCR-22-0568**.
24. Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, Hernando C, Martínez MT, Carbonell-Asins J, Simón S, Poveda J, Moragón S, Zazo S, Martínez D, Rovira A, Burgués O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, **Arribas J**, Eroles P, Cejalvo JM.. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer (2022) **Science Advances** 8 :eabk2746.
25. Pellegrino, B., Herencia-Ropero, A., Llop-Guevara, A., Pedretti, F., Moles-Fernández, A., Viaplana, C., Villacampa, G., Guzman, M., Rodriguez, O., Grueso, J., Jimenez, J., Arenas, E., Degasperis, A., Dias, J. M., V. Forment, J. V., O'Connor, M. J., Déas, O., Cairo, S., Zhou, Y., Musolino, A., Caldas, C., Nik-Zainal, S., Clarke, R., Nuciforo, P., Díez, O., Serres-

- Créixams, X., Peg, V., Espinosa-Bravo, M., Macarulla, T., Oaknin, A., Mateo, J., **Arribas, J.**, Dienstmann, R., Bellet, M., Oliveira, M., Saura, C., Balmaña, J., Serra, V. Preclinical in vivo validation of the RAD51 test for identification of homologous recombination-deficient tumors and patient stratification (2022) **Cancer Res** 82, 1646-1657.
26. Bellio C, Emperador M, Castellano P, Gris-Oliver A, Canals F, Sánchez-Pla A, Zamora E, **Arribas J**, Saura C, Serra V, Tabernero J, Littlefield BA, Villanueva J. GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells (2022) **Cancers (Basel)** 14, 2562.
- 2021
27. Arenas, E. J., Martínez-Sabadell, A., Rius Ruiz, I., Román Alonso, M., Escorihuela, M., Luque, A., Fajardo, C. A, Gros, A., Klein, C. **Arribas J**. Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation (2021). **Nature Comm.** 12, 1237.
28. Bilal, F., Arenas, E. J., Pedersen, K., Martínez-Sabadell, A., Nabet, B., Guruceaga, E., Vicent, S., Tabernero, J., Macarulla, T. and **Arribas, J**. The transcription factor Slug uncouples pancreatic cancer progression from the Raf-Mek1/2-Erk1/2 pathway (2021) **Cancer Research** 81, 3849.
29. García-Valverde A, Rosell J, Sayols S, Gómez-Peregrina D, Pilco-Janeta DF, Olivares-Rivas I, de Álava E, Maurel J, Rubió-Casadevall J, Esteve A, Gut M, Valverde C, Barretina J, Carles J, Demetri GD, Fletcher JA, **Arribas J***, Serrano C*. E3 ubiquitin ligase Atrogin-1 mediates adaptive resistance to KIT-targeted inhibition in gastrointestinal stromal tumor. **Oncogene**. 2021 Oct 7. doi: 10.1038/s41388-021-02049-0

Collaborations

30. Alison E. Smith, Emanuela Ferraro, Anton Safonov, Cristina Bernado Morales, Enrique J. Arenas Lahuerta, Qing Li, Amanda Kulick, Dara Ross, David B. Solit, Elisa de Stanchina, Jorge Reis-Filho, Neal Rosen, **Joaquín Arribas**, Pedram Razavi, Sarat Chandarlapaty. HER2+ breast cancers evade anti-HER2 therapy via a switch in driver pathway. **Nature Comm.** 12, 6667.
31. Loo Yau, H., Bell, E., Ettayebi, I., Campos de Almeida, F., Boukhaled, G. M., Shen, S. Y., Allard, D., Moranco, B., Marhon, S. A., Ishak, C. A., Gonzaga, I., Medina, T., Singhanian, R., Chakravarthy, A, Chen, R., Mehdipour, P., Pommey, S., Klein, C., Amarante-Mendes, G., Roulois, D., **Arribas, J.**, Stagg, J. & D. De Carvalho, D. DNA hypomethylating agents increase activation and cytolytic activity of CD8+ T-cells (2021) **Molecular Cell**, 8,1469-1483.
32. Guardia C, Bianchini G, Arpi-LLucià O, Menendez S, Casadevall D, Galbardi B, Dugo M, Servitja S, Montero JC, Soria-Jiménez L, Sabbaghi M, Peña R, Madoz-Gúrpide J, Lloveras B, Lluch A, Eroles P, **Arribas J**, Pandiella A, Gianni L, Rojo F, Rovira A, Albanell J. Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer. **Clin Cancer Res**. 2021 Sep 15;27(18):5096-5108. doi: 10.1158/1078-0432.CCR-20-2915.
33. Sanz-Moreno, A., Palomerias, P., Pedersen, K., Moranco, B., Pascual, T., Galván, P., Benítez, S., Gomez-Miragaya, J., Ciscar, M., Jimenez, M., Pernas, S., Petit, A., Soler-Monsó, M. T., Viñas, G., Alsaleem, M., Rakha, E. A., Green, A., R., Santamaria, P. G., Mulder, C., Lemeer, S., **Arribas, J.**, Prat, A., Puig, T., Gonzalez-Suarez, E. RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer (2021) **Breast Cancer Res** 23, 42
34. Gris-Oliver, A., Ibrahim, Y. H., Rivas, M. A., García-García, C., Sánchez-Guixé, M., Ruiz-Pace, F., Viaplana, C., Pérez-García, J. M., Llombart-Cussac, A., Grueso, J., Parés, M., Guzmán, M., Rodríguez, O., Anton, P., Cozar, P., Calvo, M. T., Bruna, A., **Arribas, J.**, Caldas, C., Dienstmann, R., Nuciforo, P., Oliveira, M., Cortés, J. & Serra, V. PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. (2021). **Brit J Cancer** 124, 1581.

35. Kumar, R., Hortobaghy, G. N., Albanell, J., **Arribas, J.** & Norton, L. In Memoriam: José Baselga's Journey in Cancer Medicine. (2021). [**Clin Cancer Res** 27, 3499](#)
 36. Ferronato MJ, Nadal Serrano M, Arenas Lahuerta EJ, Bernadó Morales C, Paolillo G, Martínez-Sabadell Aliguer A, Santalla H, Mascaró M, Vitale C, Fall Y, **Arribas J**, Facchinetti MM, Curino AC. Vitamin D analogues exhibit antineoplastic activity in breast cancer patient-derived xenograft cells. **J Steroid Biochem Mol Biol** . 2021 Apr;208:105735. doi: 10.1016/j.jsbmb.2020.105735. Epub 2020 Aug 9
- 2020
37. Cortés, J., Perez García, J. M., Llombart Cussac, A., Curigliano, G., El Saghir, N. S., Cardoso, F., Barrios, C. H., Wagle, S., Roman, J., Harbeck, N., Eniu, A., Kaufman, P. A., Tabernero, J., García Estévez, L., Schmid, P. & **Arribas, J.** Enhancing global access to cancer medicines. [**CA Cancer J Clin** 70, 105-124](#) (2020).
 38. Nadal-Serrano, M., Moranco, B., Escrivá de Romaní, S., Morales, C. B., Luque, A., Escorihuela, M., Espinosa-Bravo, M., Peg, V., Dijcks, F. A., Dokter, W. H. A., Cortés, J., Saura, C. & **Arribas, J.** The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1. [**Cancers** 12, 670–14](#) (2020).
 39. Serrano, C., Vivancos, A., López-Pousa, A., Matito, J., Mancuso, F. M., Valverde, C., Quiroga, S., Landolfi, S., Castro, S., Dopazo, C., Sebio, A., Virgili, A. C., Menso, M. M., Martín-Broto, J., Sansó, M., García-Valverde, A., Rosell, J., Fletcher, J. A., George, S., Carles, J. & **Arribas, J.** Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors. [**BMC Cancer** 5:20\(1\):99](#) (2020).

Collaborations

40. Ferronato, M.J., Nadal Serrano, M., Arenas Lahuerta, E.J., Bernadó Morales, C., Paolillo, G., Martínez-Sabadell Aliguer, A., Santalla, H., Mascaró, M., Vitale, C., Fall, Y., **Arribas, J.**, Facchinetti, M. M., Curino, A. C. Vitamin D analogues exhibit antineoplastic activity in breast cancer patient-derived xenograft cells. [**J Steroid Biochem Mol Biol**. 105735](#) (2020). Aug 9;105735. doi: 10.1016/j.jsbmb.2020.105735. Online ahead of print.
41. Gris-Oliver, A., Palafox, M., Monserrat, L., Brasó-Maristany, F., Òdena, A., Sánchez-Guixé, M., Ibrahim, Y. H., Villacampa, G., Grueso, J., Parés, M., Guzman, M., Rodríguez, O., Bruna, A., Hirst, C. S., Barnicle, A., de Bruin, E. C., Reddy, A., Schiavon, G., **Arribas, J.**, Mills, G. B., Caldas, C., Dienstmann, R., Prat, A., Nuciforo, P., Razavi, P., Scaltriti, M., Turner, N. C., Saura, C., Davies, B. R., Oliveira, M. & Serra, V. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. [**Clin Cancer Res** 26\(14\):3720-3731](#) (2020).
42. Mateo, L., Duran-Frigola, M., Gris-Oliver, A., Palafox, M., Scaltriti, M., Razavi, P., Chandarlapaty, S., Arribas, J., Bellet, M., Serra, V. & Aloy, P. Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. [**Genome Medicine** 12, 78–23](#) (2020).
43. García-Valverde, A., Rosell, J., Serna, G., Valverde, C., Carles, J., Nuciforo, P., Fletcher, J. A., **Arribas, J.**, Politz, O. & Serrano, C. Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. [**Molecular Cancer Therapeutics** 19, 1289–1297](#) (2020).
44. Cebrià-Costa, J. P., Pascual-Reguant, L., Gonzalez-Perez, A., Serra-Bardenys, G., Querol, J., Cosín, M., Verde, G., Cigliano, R. A., Sanseverino, W., Segura-Bayona, S., Iturbide, A., Andreu, D., Nuciforo, P., Bernadó Morales, C., Rodilla, V., **Arribas, J.**, Yelamos, J., de Herreros, A. G., Stracker, T. H. & Peiró, S. LOXL2-mediated H3K4 oxidation reduces chromatin accessibility in triple-negative breast cancer cells. [**Oncogene** 39, 79–121](#)(2020).

2019

45. Identification and characterization of Cardiac Glycosides as a novel class of broad spectrum senolytic compounds. Triana-Martínez, F., Picallos-Rabina, P., Da Silva-Álvarez, S., Pietrocola, F., Llanos, S., Rodilla, V., Soprano, E., Pedrosa, P., Ferreirós, A., Barradas, A., Hernández-González, F., Lalinde, M., Prats, N., Bernadó, C., González, P., Gómez, M.,

- Ikonomopoulou, M., Fernández-Marcos, P. J., García-Caballero, T., del Pino, P., **Arribas, J.**, Vidal, A., González-Barcia, M., Serrano, M., Loza, M. I., Domínguez, E., Collado, M. (2019) [Nat Commun. 10\(1\):4731](#)
46. Gomez-Miragaya, J., Díaz-Navarro, A., Tonda, R., Beltran, S., Palomero, L., Palafox, M., Dobrolecki, L., Vasaikar, S., Huang, C., Zhang, B., Wulf, G., Muñoz, P., Paré, L., Serra, V., Prat, A., Bruna, A., Caldas, C., **Arribas, J.**, Balmaña, J., Cruz, C., Pujana, M. A., Lewis, M., Puente, X., Gonzalez-Suarez, E. Chromosome 12p amplification in triple-negative breast cancer is associated with emergent docetaxel resistance and carboplatin sensitivity (2019) [Cancer Research 79, 4258-4270](#).
47. Merlino, G., Fiascarelli, A., Bigioni, M., Bressan, A., Carrisi, C., Bellarosa, D., Bugianesi, R., Manno, R., Bernadó Morales, C., **Arribas, J.**, Dusek, R. L., Attanasio, N., Ackroyd, J. E., Bisht, A., Huy Pham, P., Anderson, A., Swaminathan, S., Awdew, R., Uyen T. Do, T., Boyd, R. S., Kaplan, A. J., Aud, D. M., Lin Lou, S., Trang, M., Foltz, I., Lynch, C. M., Terrett, J., Wilson, K. E., Rohlf, C., Manzin, S., Pellacani, A., Binaschi, M. MEN1309/OBT076, a first-in-class Antibody Drug Conjugate (ADC) targeting CD205 in solid tumors (2019) [Mol Cancer Ther. 18, 1533-1543](#)
48. Diaz-Rodriguez, E., Pérez-Peña, J., Ríos-Luci, C., **Arribas, J.**, Ocaña, A., Pandiella, A. TRAIL receptor activation overcomes resistance to trastuzumab in HER2 positive breast cancer cells (2019) [Cancer Letters 453, 34-44](#).
49. Gorbatenko, A., Søkilde, R., Sorensen, E. E., Newie, I., Persson, H., Moranchó, B., **Arribas, J.**, Litman, T., Rovira, C., Pedersen, S. F. HER2 and p95HER2 differentially regulate miRNA expression in MCF-7 breast cancer cells and downregulate MYB proteins through miR-221/222 and miR-503 (2019) [Scientific Reports 9, 3352](#).
50. Blasco-Benito, S., Moreno, E., Seijo-Vila, M., Tundidor, I., Andradas, C., Caffarel, M. M., Caro-Villalobos, M., Urigüen, L., Díez-Alarcia, R., Moreno-Bueno, G., Hernández, L., Manso, L., Homar, P., McCormick, P. J., Bibic, L., Bernadó-Morales, C., **Arribas, J.**, Canals, M., Casadó, V., Canela, E. I., Guzmán, M., Pérez-Gómez, E., Sánchez, C. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer (2019) [Proc Natl Acad of Sci 116, 6505](#)
51. Kang, S.-A., Guan, J. S., Tan, H. J., Thike, A. A., Bernadó Morales, C., **Arribas, J.**, Wong, C. Y., Tan, P. H., Judi, M., Putti, T. C., Sohn, J., Lim, S. H., Lee, S. C. and Lim, Y. P. Elevated WBP2 expression in HER2-positive breast cancers correlates with sensitivity to trastuzumab-based neo-adjuvant therapy: A Retrospective and Multicentric Study (2019) [Clin Cancer Res 15, 2588-2600](#)
52. Lambies, G., Miceli, M., Martínez-Guillamon, C., Olivera-Salguero, R., Atanassov, B. S., Dent, S. Y. R., **Arribas, J.**, García de Herreros, A., Díaz, V. M. The TGF β -activated USP27X deubiquitinase regulates cell migration and chemo-resistance through Snail1 stabilization (2019) [Cancer Res 79, 33-46](#).

2018

53. Rius Ruiz I, Vicario R, Moranchó B, Bernadó Morales C, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V2, Rubio I, Cortés J, Serra V, Escrivá-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, Seoane J, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M3, Saura C, Klein C, **Arribas J.** p95HER2-T Cell Bispecific Antibody for Breast Cancer Treatment (2018) [Sci Transl Med 461, eaat1445](#).
54. Serrano, C., García-del-Muro, X., Valverde, C., Sebio, A., Durán, J., Manzano, A., Pajares, I., Hindi, N., Landolfi, S., Jiménez, L., Rubió-Casadevall, J., Estival, A., Lavernia, J., Safont, M. J., Pericay, C., Díaz-Beveridge, R., Martínez-Marín, V., Vicente-Baz, D., Vivancos, A., Hernández-Losa, J., **Arribas, J.***, Carles, J.* (2018) Clinicopathological and molecular characterization of metastatic gastrointestinal stromal tumors patients with prolonged benefit to frontline imatinib. [Oncologist 2018 Aug 20. pii: theoncologist.2018-0032](#)

Collaborations

55. Méndez, O. Peg, V., Salvans, C., Pujals, M., Fernández, Y., Abasolo, I., Pérez, J., Matres, A., Valeri, M., Gregori, J., Villarreal, J., Schwartz Jr, S., Ramon y Cajal, S., Tabernero, J., Cortés, J., **Arribas, J.**, Villanueva, J. Extracellular HMGA1 promotes Triple-Negative Breast Cancer Invasion and Metastasis by regulating tumor cell adhesion through RAGE signalling (2018) [Clin Cancer Res 24, 6367-6382](#).
 56. Cruz, C., Llop-Guevara, A., E. Garber, J. E., Arun, B. K., Pérez Fidalgo, J. A., Lluch, A., Telli, M. L., Fernández, C., Kahatt, C., Galmarini, C. M., Soto-Matos, A., Alfaro, V., Pérez de la Haza, A., Domcheck, S. M., Antolin, S., Vahdat, L., Tung, N. M., Lopez, R., **Arribas, J.**, Vivancos, A., Baselga, J., Serra, V., Balmaña, J. & Isakoff, S. J. (2018) Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Sub-study (2018) [J Clin Oncol 36, 3134-3143](#).
 57. Georgilis, A., Klotz, S., Hanley, C. J., Herranz, N., Weirich, B., Moranco, B., Leote, A. C., D'Artista, L., Gallage, S., Seehawer, M., Carroll, T., Dharmalingam, G., Keng Boon, D. W., Mellone, M., Pombo, J., Heide, D., Guccione, E., **Arribas, J.**, Barbosa-Morais, N. L., Heikenwalder, M., Thomas, G. J., Zender, L. and Gil, J. PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells (2018) [Cancer Cell 34, 85-102](#).
 58. Serrano-Candelas, E., Ainsua-Enrich, E., Navinés-Ferrer, A., Rodrigues, P., García-Valverde, A., Bazzocco, S., Macaya, I., **Arribas, J.**, Serrano, C., Sayós, J., Arango, D. and Martín, M. (2018) Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRα receptors expression and impairs gastrointestinal stromal tumors growth (2018) [Molecular Oncology 12, 1383-1397](#).
 59. Cruz, C., Castroviejo-Bermejo, M., Gutiérrez-Enríquez, S., Llop-Guevara, A., Ibrahim, Y. H., Gris-Oliver A., Bonache, S., Moranco, B., Bruna, A., Rueda, O. M., Lai, Z., Polanska, U. M., Jones, G. N., Kristel, P., de Bustos, L., Guzman, M., Rodriguez, O., Grueso, J., Montalbán, G., Caratú, G., Mancuso, F., Fasani, R., Jiménez, J., Howat, W. J., Dougherty, B., Vivancos, A., Nuciforo, P., Serres-Créixams, X., Rubio, I. T., Oaknin, A., Cadogan, E., Barrett, J. C., Caldas, C., Baselga, J., Saura, C., Cortés, J., **Arribas, J.**, Jonkers, J., Díez, O., O'Connor, M. J., Balmaña, J., Serra, V. (2018) RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA mutated breast cancer. [Ann Oncol 29, 1203-1210](#).
 60. Floros, K., Lochmann, T., Bin Hu, B., Monterrubio, C., Hughes, H., Wells, J., Bernadó Morales, C., Ghotra, M., Harada, H., Costa, C., Souers, A., Levenson, J., Tan, M., Serra, V., Koblinski, J., **Arribas, J.**, Miller, T., Dozmorov, M., Windle, B., Scaltriti, M. and Faber, A (2018) Co-amplification of miR-4728 protects HER2-amplified breast cancers from targeted therapy. [Proc Natl Acad Sci 115:E2594-E2603](#).
 61. Gawrzak, S., Rinaldi, L., Arenas, E. J., Salvador, F., Gregorio, S., Rojo, F., del Barco Barrantes, I., Cejalvo, J. M., Palafox, M., Guiu, M., Berenguer-Llargo, A., Symeonidi, A., Urosevic, J., Bellmunt, A., Kalafatovic, D., Arnal-Estapé, A., Fernández, E., Müllauer, B., Groeneveld, R., Slobodnyuk, K., Stephan-Otto Attolini, C., Saura, C., **Arribas, J.**, Cortes, J., Ana Rovira, A., Muñoz, M., Lluch, A., Serra, V., Albanell, J., Prat, A., Nebreda, A. R., Aznar-Benitah, S. & Gomis, R. R. (2018) MSK1 regulates luminal cell differentiation and metastatic dormancy in breast cancer [Nature Cell Biol 20, 211-221](#).
- 2017
62. Pedersen, K. Bilal, F., Bernadó Morales, C., Salcedo, M., Macarulla, T., Massó-Vallés, D., Mohan, V. Vivancos, A., Carreras, M.J., Serres, X., Abu-Suboh, M. Balsells, J., Allende E., Sagi, I., Soucek, L., Tabernero, T. and **Arribas J.** (2017) Pancreatic Cancer Heterogeneity and Response to anti-Mek Therapy. [Oncogene 6, 5639-5647](#).
 63. Moranco, B., Zacarías-Fluck, M., Esgueva, A., Bernadó Morales, C. Di Cosimo, S., Cortés, J., **Arribas, J.*** and Rubio, I. T.* (2016) Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. [Oncotarget 7, 67956-67965](#). *Co-corresponding authors

Collaborations

64. Martín-Pérez, R., Yebes, R., Mora-Molina, R., Cano- González, A., **Arribas, J.**, Mazzone, M., López- Rivas, A. and Palacios, C. (2017) Oncogenic p95HER2/611CTF primes human breast epithelial cells for metabolic stress-induced down-regulation of FLIP and activation of TRAIL-R/Caspase-8-dependent apoptosis. [Oncotarget 8, 93688-93703](#).
65. Ríos-Luci , C., García-Alonso , S., Díaz-Rodríguez , E., Nadal-Serrano, M., **Arribas , J.**, Ocaña, A. and Pandiella, A. (2017) Resistance to the Antibody-Drug Conjugate T-DM1 Is Based in a Reduction in Lysosomal Proteolytic Activity. [Cancer Res 77, 4639-4651](#).
66. A Sabbaghi , M., Gil-Gómez , G., Guardia , C., Servitja , S., Arpi, O., García-Alonso, S., Menéndez, S., Arumi-Uria, M., Serrano, L., Salido, M., Muntasell, A., Martinez-Garcia, M., Zazo, S., Chamizo, C., González-Alonso, P., Madoz-Gúrpide, J., Eroles, P., **Arribas, J.**, Tusquets, I., Lluch, A., Pandiella , A., Rojo, F., Rovira A. and Albanell, J. (2017) Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. [Clin Cancer Res 23, 7006-7019](#).
67. Byrne, A. T., Alférez, A. G., Amant, F., Annibali, D., **Arribas, J.**, Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., Clarke, R. B., Clevers, H., Coukos, G., Dangles-Marie, V., Eckhardt, S. G. , Gonzalez-Suarez, E. G. , Els Hermans, E, Hidalgo, M., Jarzabek, M., de Jong, S., Jonkers, J., Kemper, K., Lanfrancone, L., Mælandsmo, G. M., Marangoni, E., Marine, J.-C., Enzo Medico, E., Norum, J. H., Palmer, H. G., Peeper, D. S., Pelicci, P.G., Piris, A., Roman-Roman, S., Rueda, O. M., Seoane, J., Serra, V., Soucek, L., Vanhecke, D., Villanueva, A., Vinolo, E., Bertotti, A., Trusolino, L. (2017) Interrogating open issues in cancer precision medicine using Patient- Derived Xenograft Models. [Nature Rev Cancer 17, 254-268](#).

2016

68. Hutchinson, E., Pujana M. A. and **Arribas, J.** (2016) Cancer therapeutic resistance: progress and perspectives. *Drugs of Today* 52, 347-354.

Collaborations

69. Serra-Musach, J., Mateo, F., Capdevila-Busquets, E., de Garibay, G.R., Zhang, X., Guha, R., Thomas, C. J., Gureso, J., Villanueva, A., Jaeger, S., Heyn, H., Vizoso, M., Pérez, H., Cordero, A., Gonzalez-Suarez, E., Esteller, M., Moreno-Bueno, G., Tjärnberg, A., Lazaro, C., Serra, V., **Arribas, J.**, Benson, M., Gustafsson, M., Ferrer, M., Patrick Aloy, P. and Miguel Angel Pujana, M. A. (2016) Cancer network activity associated with therapeutic response and synergism. [Genome Medicine 24, 88](#).
70. Esparís-Ogando, A., Montero, J. C., **Arribas, J.**, Ocaña, A. and Pandiella, A. (2016) Targeting the EGF/HER Ligand-Receptor System in Cancer. [Curr Pharm Des 22, 5887-5898](#).
71. Hergueta-Redondo, M., Sarrio D, Molina-Crespo, Á, Vicario, R. Bernadó Morales, C. Martínez, L. Rojo-Sebastián, A., Serra-Musach, J., Mota, A., Martínez-Ramírez, A., Castilla, M.Á., González-Martin, A., Pernas, S., Cano, A. Cortes, J., Nuciforo, PG., Peg, V., Palacios, J., Pujana, M.Á., **Arribas, J.**, and Moreno-Bueno, G. (2016). Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. [Oncotarget 7, 56295-56308](#).
72. Nuciforo, P., Thyparambil, S., Aura, C., Garrido-Castro, A., Marta Vilaro, M., Peg, V., Jimenez, J. Hoos, W., Burrows, J., Todd Hembrough, T., Ferreres, J. C., Perez-Garcia, J., **Arribas, J.**, Cortes, J., and Scaltriti, M. (2015) High HER2 protein levels measured by multiplex mass spectrometry correlate with increased overall survival in patients treated with anti-HER2 therapy. [Molecular Oncology 10, 138-147](#).

2015

73. Zacarias-Fluck, M., Morancho, B., Vicario, R., Luque-García, A., Escorihuela, M., Villanueva, J., Rubio, I. & **Arribas, J.** (2015) Effect of cellular senescence on the growth of HER2-positive breast cancers. [J Natl Cancer Inst 107 \(5\): djv020](#)

See editorial on the article: [J Natl Cancer Inst \(2015\) 107\(5\): djv091](#)

74. Moranco, B., Martínez-Barriocanal, A., Villanueva, J. and **Arribas, J.** (2015) Ectodomain shedding controls non-cell autonomous effects of oncogene-induced senescence. [Breast Cancer Res 17, 106.](#)
75. Vicario, R., Peg, V., Moranco, B., Zacarias-Fluck, M., Zhang, J., Martinez-Barriocanal, A., Navarro Jiménez, A., Aura, C., Burgues, O., Lluch, A., Cortés, J., Nuciforo, P., Rubio, I. T., Marangoni, E., Deeds, J., Boehm, M., Schlegel, R., Tabernero, J., Mosher, R., **Arribas, J.** (2015) Patterns of HER2 gene amplification and response to anti-HER2 therapies. [PLoS One, 10\(6\):e0129876.](#)

Collaborations

76. Massó-Vallés, D., Jauset, T., Serrano, E., Pedersen, K., Affara, N., Whitfield, J., Beaulieu, M. -E., Sodik, N., Evan, G. I., Elias, L., **Arribas, J.** and Soucek, L. (2015) Ibrutinib reduces fibrosis and improves the outcome of standard therapy in a preclinical model of pancreatic adenocarcinoma. [Cancer Res 75, 1675-1681.](#)
77. Scaltriti, M., Nuciforo, P., Bradbury, I., Sperinde, J., Agbor-Tarh, D., Chenna, A., Winslow, J., Serra, V., [Parra, J.-Ll.](#), Prudkin, I., Jimenez, J., Aura, C., Harbeck, N., Pusztai, L., Ellis, C., Eidtmann, H., **Arribas, J.**, Cortes, J., de Azambuja, E. Piccart, M. & Baselga, J. (2015) High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. [Clin Cancer Res 21, 569-576.](#)

2014

78. Parra-Palau, J. Ll., Moranco, B., Peg, P., Scaltriti, M., Vicario, R., Zacarias-Fluck, M., [Pedersen, K.](#), Pandiella, A., Nuciforo, P., Serra, V., Cortés, J., Baselga, J., M. Perou, C. M., Prat, A., Rubio, I & **Arribas J.** (2014) Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. [J Natl Cancer Inst 106, dju291](#)

See comment on the article in [Cancer Discovery](#)

79. Pedersen, K., Canals, F., Tabernero, J. and **Arribas, J.** PELO negatively regulates HER-receptor signaling and metastasis (2014) [Oncogene 33, 1190-1197.](#)

Collaborations

80. García-Parra, J., Arpí, O., Moranco, B., Dalmases, A., Menendez, S., Zazo, S., Chamizo C., Eroles, P., Servitja, S., Tusquets, I., Yelamos, J., Lluch, A., **Arribas, J.**, Rojo, F., Rovira, A. and Albanell, J. (2014) Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumor activity in HER2 overexpressing breast cancer [Eur J Can 50, 2725-2734.](#)
81. Gregori, J., Méndez, O., Katsila, T., Pujals, M., Salvans, C., Villarreal, L., **Arribas, J.**, Tabernero, J., Sánchez, A. and Villanueva, J. (2014) Enhancing the Biological Relevance of Secretome-based Proteomics by Linking Tumor Cell Proliferation and Protein Secretion. [J Proteom Res 13, 3706-3721.](#)

2013

82. Angelini, P. D., Zacarias-Fluck, M. F., Parra-Palau, J. Ll., Guiu, M., Pedersen, K., Bernadó Morales, C., Luque-García, A., Peiró Novalpotro, N., Giralt, J., Canals, F., Villanueva, J., Gomis, R. R., Baselga, J. and **Arribas, J.** (2013) Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence. [Cancer Res, 73, 450-458.](#)

See comment on the article in [Breast Cancer Res \(2013\) 15, 309](#)

83. Moranco, B., Parra-Palau, J. Ll., Ibrahim, Y. H., Bernadó Morales, C., Bech-Serra, J. J., Pandiella, A., Canals, F., Baselga, J. and **Arribas, J.** (2013) A dominant negative N-terminal fragment of HER2 frequently expressed in breast cancers. [Oncogene 32, 1452-1459](#)

Collaborations

84. Serra, V., Vivancos, A., Puente, X. S., Felip, E., Silberschmidt, D., Caratu, G., Parra, J. L., De Mattos-Arruda, L., Grueso, J., Hernandez-Losa, J., **Arribas, J.**, Prudkin, L., Nuciforo, P., Scaltriti, M., Seoane, J., Baselga, J. (2013) Clinical response to a lapatinib-based therapy of

a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation. [Cancer Discov 3, 1238-1244.](#)

85. Serra, V., Eichhorn, P. J. A., García-García, C., Ibrahim, Y. I., Prudkin, P., Sánchez, G., Rodríguez, O., Antón, P., Parra, J. Ll., Marlow, S., Scaltriti, M., Prat, A., **Arribas, J.**, Hahn, W. C., Kim, S. Y. and Baselga, J. (2013) RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. [J Clin Invest, 123, 2551-2563.](#)

2012

86. Koziol, A., Gonzalo, P., Mota, A., Pollán, A., Lorenzo, C., Colomé, N., Montaner, D., Dopazo, J., **Arribas, J.**, Canals, F., Arroyo, A. G. (2012) The protease MT1-MMP drives a combinatorial proteolytic program in activated endothelial cells. [FASEB J 26, 4481-4494.](#)

2011

87. **Arribas, J.**, Baselga, J., Pedersen, K. and Parra-Palau, J. Ll. (2011) p95HER2 and breast cancer. [Cancer Res 71, 1515-1519.](#)
88. Malapeira, J., Esselens, C., Bech-Serra, J. J. Canals F., **Arribas J.** (2011) ADAM17 (TACE) regulates TGFbeta signaling through the cleavage of vasorin. [Oncogene 30, 1912-1922.](#)

Collaborations

89. Esteve, P., Sandonis, A., Cardozo, M., Malapeira, J., Ibañez, C., Crespo, I., Gonzalez-Garcia, S., Marcos, S., Torribio, M. L., **Arribas, J.**, Shimono, A., Guerrero, I. and Bovolenta, P. (2011) SFRPs act as negative modulators of ADAM10 to regulate retinal neurogenesis. [Nat Neurosci 14, 562-569.](#)
90. Serra, V., Scaltriti, M., Prudkin, L., Eichhorn, P., Ibrahim, Y. H., Chandarlapaty, S., Markman, B., Rodríguez, O., Guzman, M., Rodríguez, S., Gili, M., Russillo, M., Parra, J. Ll., Singh, S., **Arribas, J.**, Rosen, N., and Baselga, J. (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2 overexpressing breast cancer. [Oncogene 30, 2547-2557.](#)

2010

91. Parra-Palau, J. Ll., Pedersen, K., Peg, V., Scaltriti, M., Angelini, P. D., Escorihuela, M., Mancilla, S., Sánchez-Pla, A., Ramón y Cajal, S., Baselga, J., **Arribas, J.** (2010) A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the downmodulation of the ER in HER2-positive breast cancers. [Cancer Res 70, 8537-8546.](#)
92. **Arribas, J.**, Parra-Palau, J. L., Pedersen, K. (2010) HER2 fragmentation and breast cancer stratification. [Clin Can Res 16, 4071-4073.](#)
93. Esselens, C., Malapeira, J., Colomé, N., Casal, C., Rodríguez-Manzanique, J. C., **Canals, F.** and **Arribas, J.** (2010) The cleavage of semaphorin 3C induced by ADAMTS1 promotes cell migration. [J Biol Chem 285, 2463-2473.](#)

Collaborations

94. Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., Gagnon, R., Koehler, M., Gomez, H., Geyer, C., Cameron, D., **Arribas, J.**, Rosen, N. and Baselga J. (2010) Clinical Benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor-2-positive breast tumors coexpressing the truncated p95HER2 receptor. [Clin Cancer Res 16, 2688-2695.](#)
95. Chandarlapaty, S., Scaltriti, M., Angelini, P., Ye, Q., Guzman, M., Hudis, C. A., Norton, L., Solit, D. B., **Arribas, J.**, Baselga, J. and Rosen, N. (2010) Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. [Oncogene 29, 325-334.](#)

2009-1990

96. Pedersen, K., Angelini, P.-D., Laos, S., Bach-Faig, A., Cunningham, M.-P., Ferrer-Ramón, C., Luque-García, A., García-Castillo, J., Parra-Palau, J.-Ll., Scaltriti, M., Ramón y Cajal, S.,

Baselga J. and **Arribas, J.** (2009) A Naturally Occurring HER2 Carboxy-Terminal Fragment Promotes Mammary Tumor Growth and Metastasis. [Mol Cell Biol 29, 3319-3331](#).

Article Recommended by [Faculty of 1000](#)

97. García-Castillo, J., Pedersen, K., Angelini, P. D., Bech-Serra, J. J., Colome, N., Cunningham, M. P., Parra Palau, J. Ll., Canals, F., Baselga, J. and **Arribas, J.** (2009) HER2 carboxy terminal fragments regulate cell migration and cortactin phosphorylation. [J Biol Chem 284, 25302-25313](#).
98. **Arribas, J.** and Esselens, C. (2009) ADAM17 as a Therapeutic Target in Multiple Diseases. [Curr Pharm Des 15, 2319-2335](#).
99. Scaltriti, M., Verma, C., Guzman, M., Jimenez, J., Parra, J. Ll., Pedersen, K., Smith, D. J., Landolfi, S., Ramon y Cajal, S., **Arribas, J.** and Baselga, J. (2009). Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. [Oncogene 28, 803-814](#).
100. Serra, V., Markman, B., Scaltriti, M., Eichhorn, P. J., Valero, V., Guzman, M., Botero, M. L., Lluch, E., Atzori, F., Di Cosimo, S., Maira, M., Garcia-Echeverria, C., Parra, J. Ll., **Arribas, J.** and Baselga, J. (2008) NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. [Cancer Res. 68:8022-8030](#).
101. Vilar, E., Scaltriti, M., Balmana, J., Saura, C., Guzman, M., **Arribas, J.**, Baselga, J. and Tabernero J. (2008) Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. [Br J Cancer. 99,1607-1612](#).
102. Scaltriti, M., Rojo, F., Ocaña, A., Anido, J., Guzman, M., Cortes, J., Di Cosimo, S., Matias-Guiu, X., Ramon y Cajal, S., **Arribas, J.**, & Baselga, J. (2007) p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. [J Natl Cancer Inst. 99, 628-638](#).
103. Esselens, C. W., Malapeira, J., Colome, N., Moss, M., Canals, F. and **Arribas, J.** (2008) Metastasis-associated C4.4A, a GPI-anchored protein cleaved by ADAM10 and ADAM17. [Biol Chem. 389, 1075-1084](#).
104. Santiago-Josefat, B., Esselens, C., Bech-Serra, J. J. and **Arribas, J.** (2007) Post-transcriptional upregulation of ADAM17 upon EGFR activation and in breast tumors. [J Biol Chem 282, 8325-8331](#).

Article Recommended by [Faculty of 1000](#)

105. **Arribas, J.**, Bech Serra, J. J. and Santiago-Josefat, B. (2006) ADAMs, cell migration and cancer [Cancer Met Rev 25, 57-68](#).
106. Bech Serra, J. J., Santiago Josefat, B., Esselens C., Saftig, P., Baselga, J. **Arribas, J.*** and Canals, F. (2006) Proteomic Identification of Desmoglein-2 and ALCAM as substrates of ADAM17 and ADAM10 by Difference Gel Electrophoresis. [Mol Cell Biol 26, 5086-5095](#) (* Corresponding autor).
107. Anido, J., Scaltriti, M., Bech Serra, J. J., Federico Rojo, F. Baselga, J. and **Arribas, J.** (2006) Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. [EMBO J. 25, 3234-3244](#).
108. Zatovicova, M., Sedlakova, O., Svastova, E., Ohradanova, A., Ciampor, F., **Arribas, J.**, Pastorek, J. and Pastorekova, S. (2005) Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17 [B J Cancer 93, 1267-1276](#)
109. **Arribas J.** and Baselga, J. (2005) Who will benefit from anti-EGFR therapy? (2005) [Lancet Oncol 6, 257-258](#).
110. **Arribas J.** (2005) Matrix metalloproteases and tumor invasion. [New Eng J Med. 352, 2020-2021](#).

111. Martínez-Arca, S., Hurtando-Küttner, M., Borroto, A., and **Arribas, J.** (2005) Recycling of cell surface proTGF- α regulates EGFR activation. [J Biol Chem 280, 36970-3697.](#)
 112. **Arribas, J.** and Ruiz-Paz, S. (2005) Regulation of ectodomain shedding. The ADAM Family of Metalloproteases. Edited by Hopper and Lendeckel. Kluwer plenum
 113. Juanes, P. P., Ferreira, L., Montero, J. C., **Arribas, J.** and Pandiella, A. (2005) N-terminal cleavage of proTGF- α occurs at the cell surface by a TACE-independent activity. [Biochem. J 389, 161-172.](#)
 114. Baselga, J. and **Arribas, J.** (2004) Treating cancer's kinase "addiction". [Nat Med 10, 786-787.](#)
 115. Helmke, B. M., Polychronidis, M., Benner, A., Thome, M., **Arribas, J.** and Deichmann, M. (2004) Melanoma metastasis is associated with enhanced expression of the syntenin gene [Oncol Rep 12, 221-228.](#)
 116. Matar, P., Rojo, F., Cassia, R., Moreno-Bueno, G., Di Cosimo, S., Guzman, M., Rodriguez, S., **Arribas, J.**, Palacios, J., Baselga, J. (2004) Combined epidermal growth factor receptor (EGFR) targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): Superiority over single-agent receptor targeting. [Clin Cancer Res 9, 1274-1283.](#)
 117. Villanueva de la Torre, T., Bech-Serra, J. J., Ruiz-Paz, S., Baselga, J., **Arribas, J.** (2004) Inactivating mutations block the Tumor Necrosis Factor- α Converting Enzyme in the early secretory pathway [Biochem Biophys Res Commun 314, 1028-1035.](#)
 118. Velasco-Loyden, G., **Arribas, J.**, López-Casillas, F. (2004) The shedding of Betaglycan is regulated by pervanadate and inhibited by TIMP-2. [J Biol Chem 279, 7721-773.](#)
 119. Borroto, A., Ruiz-Paz, S., Borrell-Pagès, M., Villanueva de la Torre, T., Merlos-Suárez, A., Blobel, C. P., Baselga, J., and **Arribas, J.** (2003). Impaired trafficking and activation of tumor necrosis factor- α -converting enzyme in cell mutants defective in protein ectodomain shedding. [J Biol Chem. 278, 25932-25939.](#)
 120. Anido, J., Matar, P., Albanell, J., Guzman, M., Rojo, F., **Arribas, J.**, Averbuch, S. & Baselga, J. (2003). ZD1839 (Gefitinib), a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2 overexpressing breast cancer cells. [Clin Cancer Res 9, 1274-83.](#)
 121. Borrell-Pagès, M., Rojo, F., Albanell, J., Baselga, J., and **Arribas, J.** (2003) TACE is required for the activation of the EGFR by TGF- α in tumors, [EMBO J 22, 1114-1124.](#)
- Article classified as "Must Read" by [Faculty of 1000](#)
122. **Arribas, J.** & Merlos-Suarez, A. (2003). Shedding of plasma membrane proteins. [Curr Top Dev Biol 54,125-144.](#)
 123. **Arribas, J.** & Borroto, A. (2002). Protein Ectodomain Shedding. [Chem Rev 102, 4627-4638.](#)
 124. Mayo, I., **Arribas, J.**, Villoslada, P., Alvarez DoForno, R., Rodriguez-Vilarino, S., Montalban, X., de Sagarra, M. R., and Castano, J. G. (2002). The proteasome is a major autoantigen in multiple sclerosis. [Brain 125, 2658-2667.](#)
 125. Baselga, J., Albanell, J., Molina, M., and **Arribas, J.** (2001). Mechanism of action of trastuzumab and scientific update. [Semin Oncol 28, 4-11.](#)
 126. Merlos-Suarez, A., Ruiz-Paz, S., Baselga, J., and **Arribas, J.** (2001). Metalloprotease-dependent Protransforming Growth Factor- α Ectodomain Shedding in the Absence of Tumor Necrosis Factor- α -converting Enzyme. [J Biol Chem. 276, 48510-48517.](#)
 127. Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., **Arribas, J.**, and Baselga, J. (2001). Trastuzumab (Herceptin), a Humanized Anti-HER2 Receptor Monoclonal Antibody,

- Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells. [Cancer Res 61, 4744-4749](#).
128. Velasco, G., Cal, S., Merlos-Suarez, A., Ferrando, A. A., Alvarez, S., Nakano, A., **Arribas, J.**, and Lopez-Otin, C. (2000). Human MT6-Matrix Metalloproteinase: Identification, Progelatinase A Activation, and Expression in Brain Tumors. [Cancer Res 60, 877-882](#).
129. Rodriguez-Vilarino, S., **Arribas, J.**, Arizti, P., and Castano, J. G. (2000). Proteolytic Processing and Assembly of the C5 Subunit into the Proteasome Complex. [J Biol Chem 275, 6592-6599](#).
130. Jesús M. Ureña, J. M., and **Arribas, J.** (2000). El transporte intracelular de proteínas. El caso del TGF-alfa. [Ciencia al Dia Internacional 3, 1-14](#).
131. Borrell-Pages, M., Fernandez-Larrea, J., Borroto, A., Rojo, F., Baselga, J., and **Arribas, J.** (2000). The Carboxy-terminal Cysteine of the Tetraspanin L6 Antigen Is Required for Its Interaction with SITAC, a Novel PDZ Protein. [Mol Biol Cell 11, 4217-4225](#).
132. Roghani, M., Becherer, J. D., Moss, M. L., Atherton, R. E., Erdjument-Bromage, H., **Arribas, J.**, Blackburn, R. K., Weskamp, G., Tempst, P., and Blobel, C. P. (1999). Metalloprotease-Disintegrin MDC9: Intracellular Maturation and Catalytic Activity. [J Biol Chem 274, 3531-3540](#).
133. Urena, J., Merlos-Suarez, A., Baselga, J., and **Arribas, J.** (1999). The cytoplasmic carboxy-terminal amino acid determines the subcellular localization of proTGF-(alpha) and membrane type matrix metalloprotease (MT1-MMP). [J Cell Sci 112, 773-784](#).
134. Fernández-Larrea, J., Merlos-Suárez, A., Ureña, J. M., Baselga, J., and **Arribas, J.** (1999). A Role for a PDZ Protein in the Early Secretory Pathway for the Targeting of proTGF- α to the Cell Surface. [Mol Cell 3, 423-433](#).
135. Merlos-Suarez, A., and **Arribas, J.** (1999). Mechanisms controlling the shedding of transmembrane molecules. [Biochem Soc Trans 27, 243-246](#).
136. Codony-Servat, J., Albanell, J., Lopez-Talavera, J. C., **Arribas, J.**, and Baselga, J. (1999). Cleavage of the HER2 Ectodomain Is a Pervanadate-activable Process That Is Inhibited by the Tissue Inhibitor of Metalloproteases-1 in Breast Cancer Cells. [Cancer Res 59, 1196-1201](#).
137. Merlos-Suarez, A., Fernandez-Larrea, J., Reddy, P., Baselga, J., and **Arribas, J.** (1998). Pro-Tumor Necrosis Factor- α Processing Activity Is Tightly Controlled by a Component That Does Not Affect Notch Processing. [J Biol Chem 273, 24955-24962](#).
138. **Arribas, J.**, Lopez-Casillas, F., and Massague, J. (1997). Role of the Juxtamembrane Domains of the Transforming Growth Factor- α Precursor and the β -Amyloid Precursor Protein in Regulated Ectodomain Shedding. [J Biol Chem 272, 17160-17165](#).
139. **Arribas, J.**, Coodly, L., Vollmer, P., Kishimoto, T. K., Rose-John, S., and Massagué, J. (1996). Diverse Cell Surface Protein Ectodomains Are Shed by a System Sensitive to Metalloprotease Inhibitors. [J Biol Chem 271, 11376-11382](#).
140. Castano, J. G., Mahillo, E., Arizti, P., and **Arribas, J.** (1996). Phosphorylation of C8 and C9 subunits of the multicatalytic proteinase by casein kinase II and identification of the C8 phosphorylation sites by direct mutagenesis. [Biochemistry 35, 3782-3789](#).
141. **Arribas, J.**, and Massague, J. (1995). Transforming growth factor- α and β -amyloid precursor protein share a secretory mechanism. [J Cell Biol 128, 433-441](#).
142. **Arribas, J.**, Arizti, P., and Castano, J. (1994). Antibodies against the C2 COOH-terminal region discriminate the active and latent forms of the multicatalytic proteinase complex. [J Biol Chem 269, 12858-12864](#).
143. Ruiz de Mena, I., Mahillo, E., **Arribas, J.**, and Castano, J. G. (1993). Kinetic mechanism of activation by cardiolipin (diphosphatidylglycerol) of the rat liver multicatalytic proteinase. [Biochem J 296, 93-97](#).

144. **Arribas, J.**, and Castano, J. (1993). A comparative study of the chymotrypsin-like activity of the rat liver multicatalytic proteinase and the ClpP from Escherichia coli. [J Biol Chem 268, 21165-21171.](#)
145. Arizti, P., **Arribas, J.**, and Castano, J. G. (1993). Modulation of the multicatalytic proteinase complex by lipids, interconversion and proteolytic processing. [Enzyme Protein 47, 285-295.](#)
146. **Arribas, J.**, Luz Rodriguez, M., Alvarez-Do Forno, R., and Castano, J. (1991). Autoantibodies against the multicatalytic proteinase in patients with systemic lupus erythematosus. [J Exp. Med. 173, 423-427.](#)
147. **Arribas, J.**, and Castano, J. (1990). Kinetic studies of the differential effect of detergents on the peptidase activities of the multicatalytic proteinase from rat liver. [J Biol Chem 265, 13969-13973.](#)